SUBJECT INDEX

This Subject Index is compiled from key words in the title of each entry. An original article is indicated by (O), editorial (E), correspondence (C), news and notes (N), obituary (Ob), abstract (A), book review (B), supplement (S).

Acquired immunodeficiency syndrome (AIDS),
Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of *M. avium* complex. Piersimoni, C., *et al.* ..... (A) 127
AIDS-related *M. kansasii* infection with initial resistance to clarithromycin. Burman, W. J., *et al.* (A) 510
Detection of *M. tuberculosis* by PCR analysis of urine and other clinical samples from AIDS and non-HIV-infected patients. Sechi, L. A., *et al.* ..... (A) 119
Penetration of dapsone into cerebrospinal fluid of patients with AIDS. Gatti, G., *et al.* ..... (A) 110
Use of different molecular typing techniques for bacteriological follow up in a clinical trial with AIDS patients with *M. avium* bacteremia. Picardeau, M., *et al.* ..... (A) 116

Actinomycetes,
Mycobacterial linear plasmids have an invertron-like structure related to other linear replicons in actinomycetes. Picardeau, M. and Vincent, V. ..... (A) 524

Adenosine triphosphate (ATP),
ATP-induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z(P2X7) receptors. Lammas, D. A., *et al.* ..... (A) 113
Effect of trifluoperazine on *in vitro* ATP synthesis by *M. leprae*. Katoch, V. M., *et al.* ..... (A) 278
Viability determination of *M. leprae*: comparison of normal mouse foot pad and bacillary ATP bioluminescence assay. Gupta, U. D., *et al.* ..... (A) 277

Africa,
Decreased survival of HTLV-1 carriers in leprosy patients from the Democratic Republic of the Congo: a historical prospective study. Lechat, M. F., *et al.* ..... (A) 102
[Evaluation of the elimination of leprosy in Burkina Faso.] Tiendrebeogo, A., *et al.* ..... (A) 516

Allergy(ies),
Dapsone induced pulmonary eosinophilia without cutaneous allergic manifestations—an unusual encounter—a case report. Arunthathi, S. and Raju, S. ..... (A) 497
Infection of mice with *M. bovis*-bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. Erb, K. J., *et al.* ..... (A) 293
Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed *M. vaccae*. Wang, C. C. and Rook, G. A. W. ..... (A) 429

Amikacin,
Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against *M. avium*. Horgen, L., *et al.* ..... (A) 251

Amoxicillin,
Activity of amoxicillin/clavulanate in patients with tuberculosis. Chambers, H. F., *et al.* .... (A) 422

Antibody(ies),
A simple dipstick assay for the detection of antibodies to phenolic glycolipid I of *M. leprae*. Buhrer, S. S., *et al.* ..... (A) 263
Anti-PGL-I antibody levels in Thai leprosy patients. Kampirapap, K. and Singtham, N. .... (A) 266
Anti-neutrophil cytoplasmic antibodies (ANCA) in the clinical forms of leprosy. Breire, B. F. A., *et al.* ..... (O) 475
Antibodies to mycobacterial 65-kDa heat shock protein crossreact with the main mitochondrial antigens in patients with primary biliary cirrhosis. Vilagut, L., *et al.* ..... (A) 121

[Antibody to HIV-1 in the sera of leprosy patients.] Chan, J., *et al.* . . . . . (A) 85
Beta$_2$-Glycoprotein I-dependent anticardiolipin antibodies as risk factor for reactions in borderline leprosy patients. Fiallo, P., *et al.* . . . . . (C) 387
Crossreactivity of anti-10 kDa heat shock protein antibodies in leprosy and tuberculosis patients. Rojas, R. E., *et al.* . . . . . (A) 268
Detection of S-100 antigen and anticeramide antibody in sera of leprosy patients with and without reaction. Narayan, R., *et al.* . . . . . (A) 268
IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type 2 lepra reaction on thalidomide treatment. Partida Sanchez, S., *et al.* . . . . . (A) 507
IgG subclass distribution of antibody responses to protein and polysaccharide mycobacterial antigens in leprosy and tuberculosis patients. Sousa, A. O., *et al.* . . . . . (A) 270
IgM anti-phenolic glycolipid I and IgG anti-10-kDa heat shock protein antibodies in sera and immune complexes isolated from leprosy patients with or without erythema nodosum leprosum and contacts. Rojas, R. E., *et al.* . . . . . (A) 92
Involvement of antilipoarabinomannan antibodies in classical complement activation in tuberculosis. Hetland, G., *et al.* . . . . . (A) 265
Staining pattern of seven monoclonal anti-CD26 antibodies in leprosy: implications for the use of CD26 as a surrogate marker of a human Th1-like reaction. Seitzer, U., *et al.* . . . . . (A) 412

Antigen(s),
A novel 27 kDa lipoprotein antigen from *M. bovis*. Bibi, F., *et al.* . . . . . (A) 95
A novel mycobacterial antigen relevant to cellular immunity belongs to a family of secreted lipoproteins. Oftung, F., *et al.* . . . . . (A) 281
[An investigation of ABH antigens in erythrocytes and saliva of leprosy patients.] Silva, E. A., *et al.* . . . . . (A) 502
Anti-tumor immunity induced by murine melanoma cells transduced with the *M. tuberculosis* gene encoding the 38-kDa antigen. Sfondrini, L., *et al.* . . . . . (A) 302
Antibodies to mycobacterial 65-kDa heat shock protein crossreact with the main mitochondrial antigens in patients with primary biliary cirrhosis. Vilagut, L., *et al.* . . . . . (A) 121
Association of HLA-class I antigens and haplotypes with relapse or pulmonary tuberculosis in patients treated with short course chemotherapy. Selvaraj, P., *et al.* . . . . . (A) 301
Biological activities of alpha-antigen; humoral immunity and fibronectin binding. Naito, M. and Yamada, T. . . . . (A) 435
Changes in cellular response to mycobacterial antigens and cytokine production patterns in leprosy patients during multiple drug therapy. Trao, V. T., *et al.* . . . . . (A) 508
Characterization of human CD8+ T cells reactive with *M. tuberculosis*-infected antigen-presenting cells. Lewisohn, D. M., *et al.* . . . . . (A) 506
Characterization of novel immunodominant antigens of *M. tuberculosis*. Amara, R. R., *et al.* (A) 420
Cloning of the antigen 85A from *M. gordonae* and its use for the specific PCR identification of these mycobacteria. Dumonceaux, M., *et al.* . . . . . (A) 110
[Detection of *M. leprae* and PGL-I antigen in nasal secretion and skin tissue.] Weng, X., *et al.* (A) 512
Detection of S-100 antigen and anticeramide antibody in sera of leprosy patients with and without reaction. Narayan, R., *et al.* . . . . . (A) 268
Differential immunogenicity of novel *M. tuberculosis* antigens derived from live and dead bacilli. Amara, R. R. and Satchidanandam, V. . . . . (A) 107
Fractionation, characterization and diagnostic potential of circulating leprosy antigens isolated from sera of lepromatous leprosy patients. Narayan, R., *et al.* . . . . . (O) 22
IgG subclass distribution of antibody responses to protein and polysaccharide mycobacterial antigens in leprosy and tuberculosis patients. Sousa, A. O., *et al.* . . . . . (A) 270
Impaired responses to *M. leprae* antigens in rhesus monkeys experimentally inoculated with simian immunodeficiency virus and *M. leprae*. Gormus, B. J., *et al.* . . . . . (A) 418
Lymphocytes expressing Fc gamma receptors suppress antigen induced proliferation in cells from guinea pigs infected with *M. tuberculosis*. Bartow, R. A. and McMurray, D. N. . . . . (A) 518
MTC28, a novel 28-kilodalton proline-rich secreted antigen specific for the *M. tuberculosis* complex. Manca, C., *et al.* . . . . . (A) 279
Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-gamma and IL-4 knockout mice—analysis of local and regional cytokine and chemokine networks. Chensue, S. W., *et al.* . . . . . (A) 88
[On method of large preparation and purification of recombinant alpha-protein antigen.] Yin, Y., *et al.* . . . . . (A) 513
Processing of *M. tuberculosis* bacilli by human monocytes for CD4+ alpha beta and gamma delta T cells: role of particulate antigen. Balaji, K. N. and Boom, W. H. . . . . (A) 261

Production of host-protective (IFN gamma), host-impairing (IL-10, IL-13) and inflammatory (TNF alpha) cytokines by PMBC from leprosy patients stimulated with mycobacterial antigens. Machado, P., *et al.* ..... (A) 409
Requirement for different presenting cells and for different processing mechanisms by human CD4 T helper clones specific for *M. tuberculosis* antigens. Manca, F., *et al.* ..... (A) 410
Serologic assays using the 18-kDa antigen of *M. leprae* expressed in the yeast *Saccaromyces cerevisiae*. Pinho, J. R. R., *et al.* ..... (C) 235
[Serological activity of recombinant alpha-antigen of *M. leprae*.] Yin, Y., *et al.* ..... (A) 94
Single-cell cytokine analysis of gamma delta T cell responses to nonpeptide mycobacterial antigens. Garcia, V. E., *et al.* ..... (A) 90
The *in vitro* induction of human immunodeficiency virus (HIV) replication in PPD-positive HIV-infected persons by recall antigen response to *M. tuberculosis* is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. Goletti, D., *et al.* ..... (A) 424
Vaccination with plasmid DNA encoding mycobacterial antigen 85 stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by *M. tuberculosis* H37Rv infection. Denis, O., *et al.* ..... (A) 422

Apoptosis,
Apoptosis of human monocytes and macrophages by *M. avium* sonicate. Hayashi, T., *et al.* ... (A) 295
Differential induction of apoptosis by virulent *M. tuberculosis* in resistant and susceptible murine macrophages— role of nitric oxide and mycobacterial products. Rojas, M., *et al.* . (A) 92
Effect of thalidomide on apoptosis of lymphocytes and neutrophils. Aseffa, A., *et al.* ..... (A) 87
Effects of mycobacteria on regulation of apoptosis in mononuclear phagocytes. Klinger, K., *et al.* ..... (A) 266
Fas ligand-induced apoptosis of infected human macrophages reduced the viability of intracellular *M. tuberculosis*. Oddo, M., *et al.* ..... (A) 507
Induction of apoptosis in murine macrophages by *M. tuberculosis* is reactive oxygen intermediate-independent. Rojas, M., *et al.* ..... (A) 525
M. bovis bacillus Calmette Guerin infection prevents apoptosis of resting human monocytes. Kremer, L., *et al.* ..... (A) 90
M. tuberculosis exploits the CD95/CD95 ligand system of gamma delta T cells to cause apoptosis. Manfredi, A. A., *et al.* ..... (A) 523

Argentina,
Studies of vaccination of persons in close contact with leprosy patients in Argentina. Bottasso, O., *et al.* ..... (A) 504

Armadillo(s),
Cellular immune responses of healthy and *M. leprae*-inoculated armadillos (*Dasypus novemcinctus*). Rivero-Nava, L., *et al.* ..... (C) 485
The activity of rifabutin against *M. leprae* in armadillos. Dhople, A. M. and Williams, S. L. (A) 284

Arthritis,
An immunodominant epitope from mycobacterial 65-kDa heat shock protein protects against pristane-induced arthritis. Thompson, S. J., *et al.* ..... (A) 428
The effect of thalidomide and two analogs on collagen induced arthritis. Oliver, S. J., *et al.* .. (A) 427

Assay(s) (see also **ELISA**),
A rapid drug susceptibility test for *M. tuberculosis* using the hybridization protection assay. Koga, H., *et al.* ..... (A) 113
A simple dipstick assay for the detection of antibodies to phenolic glycolipid I of *M. leprae*. Buhrer, S. S., *et al.* ..... (A) 263
Evaluation of a commercial probe assay for detection of rifampin resistance in *M. tuberculosis* directly from respiratory and nonrespiratory clinical samples. Gamboa, F., *et al.* .. (A) 521
Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of *M. tuberculosis* complex and its resistance to rifampin. Rossau, R., *et al.* . (A) 118
Green fluorescent protein reporter microplate assay for high throughput screening of compounds against *M. tuberculosis*. Collins, L. A., *et al.* ..... (A) 291
Mycobacterial arabinan biosynthesis: the use of synthetic arabinoside acceptors in the development of an arabinosyl transfer assay. Lee, R. E., *et al.* ..... (A) 279
Rifampicin causes false-positive immunoassay results for urine opiates. dePaula, M., *et al.* .. (A) 501

Serologic assays using the 18-kDa antigen of *M. leprae* expressed in the yeast *Saccaromyces cerevisiae*. Pinho, J. R. R., *et al.* ..... (C) 235
Viability determination of *M. leprae*: comparison of normal mouse foot pad and bacillary ATP bioluminescence assay. Gupta, U. D., *et al.* ..... (A) 277

Australia,
A large localized outbreak of *M. ulcerans* infection on a temperate southern Australian island. Veitch, M. G. K., *et al.* ..... (A) 304

B663 (see **Clofazimine**), **Bacilli,**
Differential immunogenicity of novel *M. tuberculosis* antigens derived from live and dead bacilli. Amara, R. R. and Satchidanandam, V. ..... (A) 107
Processing of *M. tuberculosis* bacilli by human monocytes for CD4+ alpha beta and gamma delta T cells: role of particulate antigen. Balaji, K. N. and Boom, W. H. ..... (A) 261

Bacteremia,
Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to *M. avium*. May, T., *et al.* .... (A) 114
Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin and ethambutal for *M. avium* complex bacteremia: a multivariate analysis. Shafran, S. D., *et al.* ..... (A) 302
Use of different molecular typing techniques for bacteriological follow up in a clinical trial with AIDS patients with *M. avium* bacteremia. Picardeau, M., *et al.* ..... (A) 116

Bacteriology,
Use of different molecular typing techniques for bacteriological follow up in a clinical trial with AIDS patients with *M. avium* bacteremia. Picardeau, M., *et al.* ..... (A) 116

Bacteriophage,
Conditionally replicating mycobacteriophages: a system for transposon delivery to *M. tuberculosis*. Bardarov, S., *et al.* ..... (A) 107
Mycobacteriophage D29 contains an integration system similar to that of the temperate mycobacteriophage L5. Ribeiro, G., *et al.* ..... (A) 98
Mycobacteriophage L5 infection of *M. bovis* BCG: implications for phage genetics in the slow-growing mycobacteria. Fullner, K. J. and Hatfull, G. F. ..... (A) 96

Bangladesh,
Independent evaluation of leprosy elimination activities in Bangladesh, 11–23 September 1997. McDougall, A. C. ..... (C) 66

BCG (bacille Calmette-Guerin),
A case-control study of the effectiveness of the BCG vaccine for preventing leprosy in Yangon, Myanmar. Bertolli, J., *et al.* ..... (A) 101
Activation of CD8 T cells with specificity for mycobacterial heat shock protein 60 in *M. bovis* bacillus Calmette-Guerin vaccinated mice. Zugel, U. and Kaufmann, S. H. E. ..... (A) 94
An acyl-CoA synthase (acoas) gene adjacent to the mycocerosic acid synthase (mas) locus is necessary for mycocerosyl lipid synthesis in *M. tuberculosis* var. *bovis* BCG. Fitzmaurice, A. M. and Kolattukudy, P. E. ..... (A) 414
Bacille Calmette-Guerin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. Hoft, D. F., *et al.* ..... (A) 522
Effectiveness of bacillus Calmette-Guerin (BCG) vaccination in the prevention of leprosy; a case-finding control study in Nagpur, India. Zodpey, S. P., *et al.* ..... (O) 309
Expression systems for study of mycobacterial gene regulation and development of recombinant BCG vaccines. DasGupta, S. K., *et al.* ..... (A) 520
[Follow up of 25 years for prevention of leprosy with BCG vaccination.] Ma, D., *et al.* ..... (A) 287
Infection of mice with *M. bovis*-bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. Erb, K. J., *et al.* ..... (A) 293
Inhibition of multiplication of *M. leprae* in mouse foot pads by immunization with ribosomal fraction and culture filtrate from *M. bovis* BCG. Matsuoka, M., *et al.* ..... (A) 100
M. bovis bacillus Calmette Guerin infection prevents apoptosis of resting human monocytes. Kremer, L., *et al.* ..... (A) 90
Mycobacteriophage L5 infection of *M. bovis* BCG: implications for phage genetics in the slow-growing mycobacteria. Fullner, K. J. and Hatfull, G. F. ..... (A) 96

Protective immunization of monkeys with BCG or BCG plus heat killed *M. leprae*: clinical results. Gormus, B. J., *et al.* ..... (A) 417
"Proteomic contigs" of *M. tuberculosis* and *M. bovis* (BCG) using novel immobilised pH gradients. Urguhart, B. L., *et al.* ..... (A) 120
Two-dimensional electrophoretic analysis of humoral responses to culture filtrate of *M. bovis* BCG in patients with leprosy and tuberculosis. Naito, M., *et al.* ..... (O) 208

Behçet's syndrome,
Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome—a randomized, double-blind, placebo-controlled trial. Hamuryudan, V., *et al.* ..... (A) 295

Biochemistry,
Semen biochemistry of leprosy patients. Sirmour, S. K., *et al.* ..... (A) 259

Blood,
Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Eriksson, T., *et al.* ..... (A) 293

Bone,
Bone scintigraphy in leprosy. Soni, A., *et al.* ..... (C) 483
Osteoporosis due to testicular atrophy in male leprosy leprosy patients. Ishikawa, S., *et al.* .. (A) 85
Progression of bone lesions in cured leprosy patients. Carpintero, P., *et al.* ..... (A) 517
Radiological evaluation of bone changes in leprosy. Manzur, S., *et al.* ..... (A) 257

Book reviews,
Damien and Dutton, Two Josephs on Molokai by Howard E. Crouch. Hastings, R. C ..... (B) 488
Essential Surgery in Leprosy; Techniques for District Hospitals by H. Srinivasan and D. D. Palande. Mathews, R. .....(B) 69
Leprosy Minutiae by Rajiv Joshi. Hastings, R. C. .....(B) 489
The Peripheral Nerve in Leprosy and Other Neuropathies by N. H. Antia and V. R. Shetty. Hastings, R. C. ..... (B) 394

Borderline leprosy,
A sequential study of circulating immune complexes, complement and immunoglobulins in borderline tuberculoid leprosy patients with and without reactions. Ramanathan, V. D., *et al.* ..... (A) 507
Beta$_2$-Glycoprotein I-dependent anticardiolipin antibodies as risk factor for reactions in borderline leprosy patients. Fiallo, P., *et al.* ..... (C) 387
Borderline tuberculoid leprosy: clinicopathological evaluation of multidrug therapy. Kar, P. K. and Dhaka, R. S. ..... (A) 251
Contribution of type 1 reactions to sensory and motor function loss in borderline leprosy patients and the efficacy of treatment with prednisone. Roche, P. W., *et al.* ..... (O) 340
Diffuse alopecia of the scalp in borderline lepromatous leprosy in an Indian patient. Abraham, S., *et al.* ..... (A) 254
Leprosy type 1 reaction as the first manifestation of borderline lepromatous leprosy in a young native German. Biedermann, T., *et al.* ..... (A) 401
Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like *M. leprae* T-cell reactivity in lesional skin—a follow-up study. Verhagen, C. E., *et al.* ..... (A) 272
Serial Mitsuda tests for identification of reactional tuberculoid and reactional borderline leprosy forms. Lastoria, J. C., *et al.* ..... (O) 190

Brazil,
[A leprosy elimination campaign combined with a vaccine against poliomyelitis, Rio de Janeiro, Brazil.] Andrade, V., *et al.* ..... (A) 399
An epidemic of tuberculosis with a high rate of tuberculin anergy among a population previously unexposed to tuberculosis, the Yanomami Indians of the Brazilian Amazon. Sousa, A. O., *et al.* ..... (A) 303
Genetics of host resistance and susceptibility to intramacrophage pathogens: a study of multicase families of tuberculosis, leprosy and leishmaniasis in northeastern Brazil. Blackwell, J. M. ..... (A) 262
Leprosy and HIV infection in Bahia, Brazil. Machado, P., *et al.* ..... (C) 227
Monitoring the elimination of leprosy in Brazil. Andrade, V., *et al.* ..... (O) 457

[Opinions about Hansen's disease among the members of the patients' social network in Recife.] de Feliciano, K. V. and Kovacs, M. H. ..... (A) 247

Cancer,
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma. Ruff, P., *et al.* ..... (A) 428
Anti-tumor immunity induced by murine melanoma cells transduced with the *M. tuberculosis* gene encoding the 38-kDa antigen. Sfondrini, L., *et al.* ..... (A) 302
Lepromatous orchitis associated with seminoma. Ebenezer, G. J., *et al.* ..... (A) 385

Cell(s) (see also specific cells),
Ability of lymphokine-activated killer cells to lyse mycobacteria-infected cells. Chiplunkar, S. V., *et al.* ..... (A) 264
Characterization of the dnaG locus in *M. smegmatis* reveals linkage of DNA replication and cell division. Klann, A. G., *et al.* ..... (A) 278
Identification of phosphatidylinositol mannoside as a mycobacterial adhesion mediating both direct and opsonic binding in nonphagocytic mammalian cells. Hoppe, H. C., *et al.* ..... (A) 96
Lymphocytes expressing Fc gamma receptors suppress antigen induced proliferation in cells from guinea pigs infected with *M. tuberculosis*. Bartow, R. A. and McMurray, D. N. .... (A) 518
Mammalian heterotrimeric G-protein-like proteins in mycobacteria: implications for cell signalling and survival in eukaryotic host cells. Shankar, S., *et al.* ..... (A) 282
Thalidomide may impede cell migration in primates by downregulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. McCarty, M. F. ..... (A) 114
Why intracellular parasitism need not be a degrading experience for *Mycobacterium*. Russell, D. G., *et al.* ..... (A) 93

Cells, B,
Determinant capture by MHC class II DR3 during processing of *M. leprae* 65 kDa heat shock protein by human B cells. Young, S. P., *et al.* ..... (A) 412

Cells, mononuclear,
Genetic variations at the T cell receptor gamma locus in circulating peripheral blood mononu clear cells of clinically categorized leprosy patients. Sachdeva, G., *et al.* ..... (A) 287

Cells, Schwann,
Collagen profile in sciatic nerves of *M. leprae*-inoculated mice correlates with *in vitro* collagen production by Schwann cells. Singh, N., *et al.* ..... (C) 238
Effects of *M. leprae* infection on gene expression in cultured Schwann cells. Hagge, D., *et al.* (A) 432
Schwann cell extracellular matrix protein production in modulated *M. leprae* and macrophage secretory products. Singh, N., *et al.* ..... (A) 100

Cells, T,
Activation of CD8 T cells with specificity for mycobacterial heat shock protein 60 in *M. bovis* bacillus Calmette-Guerin vaccinated mice. Zugel, U. and Kaufmann, S. H. E. ..... (A) 94
Bacille Calmette-Guerin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. Hoft, D. F., *et al.* ..... (A) 522
Characterization of human CD8+ T cells reactive with *M. tuberculosis*-infected antigen-presenting cells. Lewisohn, D. M., *et al.* ..... (A) 506
Effect of T-helper cytokine environment on specificity of T cell responses to mycobacterial 65,000 MW heat-killed shock protein. Siew, L. K., *et al.* ..... (A) 412
Fine structural requirements for T-cell recognition of glucose monomycolate presented by human CD1b. Moody, D. B., *et al.* ..... (A) 434
Fractionation of mycobacterial integral membrane proteins by continuous elution SDS-PAGE reveals the immunodominance of low molecular weight subunits for human T cells. Mehrotra, J., *et al.* ..... (A) 97
Gamma delta+ and CD4+ alpha beta+ human T cell subset responses upon stimulation with various *M. tuberculosis* soluble extracts. Batoni, G., *et al.* ..... (A) 407
Genetic variations at the T cell receptor gamma locus in circulating peripheral blood mononuclear cells of clinically categorized leprosy patients. Sachdeva, G., *et al.* ..... (A) 287
Identification and characterization of protective T cells in hsp 65 DNA-vaccinated and *M. tuberculosis*-infected mice. Bonato, V. L. D., *et al.* ..... (A) 263

Identification of mycobacterial HSP70 reactive human T cell clones discriminating between *M. tuberculosis* and *M. leprae*. Oftung, F. and Lundin, K. E. A. ..... (A) 280
Identification of potential CD8+ T-cell epitopes of the 19 kDa and AhpC proteins from *M. tuberculosis*. No evidence for CD8+ T-cell priming against the identified peptides after DNA-vaccination of mice. Erb, K. J., *et al.* ..... (A) 423
Influence of mycobacterial virulence and culture condition on gamma delta T cell activation. Schoel, B. and Kaufmann, S. H. E. ..... (A) 411
Lipids from *M. leprae* cell wall suppress T-cell activation *in vivo* and *in vitro*. Moura, A. C. N. and Mariano, M. ..... (A) 267
Lymphocyte-dependent inhibition of growth of virulent *M. tuberculosis* H37Rv within human monocytes: requirement for CD4+ T cells in PPD-positive, but not PPD-negative subjects. Silver, R. F., *et al.* ..... (A) 303
M. tuberculosis exploits the CD95/CD95 ligand system of gamma delta T cells to cause apoptosis. Manfredi, A. A., *et al.* ..... (A) 523
Processing of *M. tuberculosis* bacilli by human monocytes for CD4+ alpha beta and gamma delta T cells: role of particulate antigen. Balaji, K. N. and Boom, W. H. ..... (A) 261
Protein deficiency induces alterations in the distribution of T-cell subsets in experimental pulmonary tuberculosis. Mainali, E. S. and McMurray, D. N. ..... (A) 297
Recognition of a common mycobacterial T-cell epitope in MPB59 of *M. bovis*. Lightbody, K. A., *et al.* ..... (A) 426
Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like *M. leprae* T-cell reactivity in lesional skin—a follow-up study. Verhagen, C. E., *et al.* ..... (A) 272
Single-cell cytokine analysis of gamma delta T cell responses to nonpeptide mycobacterial antigens. Garcia, V. E., *et al.* ..... (A) 90
T-cell responses to major membrane protein II (MMP II) derived from *M. leprae* in leprosy patients. Ohyama, H., *et al.* ..... (A) 435
T-cell-independent granuloma formation in response to *M. avium*: role of tumour necrosis factor-alpha and interferon gamma. Smith, D., *et al.* ..... (A) 270
The T cell receptor subsets of lymphocytes in bronchoalveolar lavage in patients with active pulmonary tuberculosis. Uh, S. T., *et al.* ..... (A) 428
Type 1- and type 2-like skin-derived *M. leprae*-responsive T cell clones are characterized by coexpression of IFN-gamma/TNF-alpha and IL-4/IL-5/IL-13, respectively. Verhagen, C. E., *et al.* ..... (A) 271
Vaccination with plasmid DNA encoding mycobacterial antigen 85 stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by *M. tuberculosis* H37Rv infection. Denis, O., *et al.* ..... (A) 422

Cell-mediated immunity (CMI),
A novel mycobacterial antigen relevant to cellular immunity belongs to a family of secreted lipoproteins. Oftung, F., *et al.* ..... (A) 281
Association of polymorphism at COL3A and CTLA4 loci on chromosome 2q31–33 with the clinical phenotype and *in vitro* CMI status in healthy and leprosy subjects: a preliminary study. Kaur, G., *et al.* ..... (A) 287

Chemotherapy (see also **Multidrug therapy**),
Association of HLA-class I antigens and haplotypes with relapse or pulmonary tuberculosis in patients treated with short course chemotherapy. Selvaraj, P., *et al.* ..... (A) 301
DNA amplification for detection of leprosy and assessment of efficacy of leprosy chemotherapy. Kampirapap, K., *et al.* ..... (O) 16
Emergence of *M. avium* populations resistant to macrolides during experimental chemotherapy. Bermudez, L. E., *et al.* ..... (A) 290
Global elimination of leprosy. Gillis, T. P. and Krahenbuhl, J. L. ..... (A) 399

Children,
[Leprosy among children 14 years old in Guangzhou.] Tan, X. ..... (A) 503
Profile of leprosy in children: past and present. Ebenezer, L., *et al.* ..... (A) 285
The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Rovelli, A., *et al.* ..... (A) 301

China,
[A survey of the social estate of leprosy patients.] Chen, J. ..... (A) 105
Blindness and low vision in leprosy patients in Sichuan Province, China. Yang, J., *et al.* ..... (A) 406

[Differences of subclinical infection rates and onset of leprosy between various villages in a high-endemic area.] Shen, J., *et al.* ..... (A) 103
[Disability among 1522 cases of leprosy using MDT.] Dan, Z., *et al.* ..... (A) 105
[Effect of minocycline made in China on vitality of *M. leprae* in nude mice.] Wang, H., *et al.* (A) 418
[Effects of MDT for 13 years in Mengla County, Yunnan.] Ma, J. ..... (A) 103
[Endemic situation of leprosy in 1996, Guangdong.] Zheng, D., *et al.* ..... (A) 105
[Five-year monitoring for 120 persons who had MB leprosy and used MDT.] Lai, Z., *et al.* .. (A) 81
Fourth Congress of the China Leprosy Association. He, D. ..... (N) 492
[Leprosy among children 14 years old in Guangzhou.] Tan, X. ..... (A) 503
[Leprosy control in Chencen town of Shunde County, Guangdong.] Feng, Z. ..... (A) 502
[Leprosy endemic and its control in Yunnan Province.] Xu, K., *et al.* ..... (A) 104
[Leprosy in Guangzhou city before and after MDT.] Ma, Q. ..... (A) 103
[Monitoring for ten years after basic eradication of leprosy.] Mo, S. ..... (A) 418
[On optimal input of resources for leprosy control after its basic eradication.] Xu, Y., *et al.* .. (A) 79
Present situation of eye care and research in leprosy in China. Yao, J. and Qian, J. ..... (A) 406
[Relapse of 46 cases of leprosy in Wuxi, Jiangsu.] Li, B., *et al.* ..... (A) 498
[Socio-medical investigation on leprosy following MDT (I); knowledge, attitude and behaviour of leprosy patients to MDT.] Chen, X., *et al.* ..... (A) 79
[Study on the recent trends of leprosy epidemiology in Yangzhou Prefecture and Dongtai City, Jiangsu Province.] Shen, J., *et al.* ..... (A) 104
The current situation of lagophthalmos and keratopathy of leprosy in PR China. Jiang, J. and Wei, X. Y. ..... (A) 404

Chromosome(s),
Association of polymorphism at COL3A and CTLA4 loci on chromosome 2q31–33 with the clinical phenotype and *in vitro* CMI status in healthy and leprosy subjects: a preliminary study. Kaur, G., *et al.* ..... (A) 287
Use of a *M. tuberculosis* H37Rv bacterial artifical chromosome library for genome mapping, sequencing, and comparative genomics. Brosch, R., *et al.* ..... (A) 413

Classification,
Sensitivity and specificity of methods of classification of leprosy without use of skin-smear examination. Croft, R. P., *et al.* ..... (O) 445

Clinical,
Alpha-1-antichymotrypsin is not associated with the increased frequency of apolipoprotein-E-epsilon-4 allele in elderly nondemented leprosy patients. Endoh, M., *et al.* ..... (A) 257
Anti-neutrophil cytoplasmic antibodies (ANCA) in the clinical forms of leprosy. Breire, B. F. A., *et al.* ..... (O) 475
[Analysis of 108 aged cases of leprosy.] Wang, J., *et al.* ..... (A) 406
Arsenic poisoning mimicking polyneuritis leprosy. Sharma, V., *et al.* ..... (A) 229
Articular inflammatory manifestations in patients with different forms of leprosy. Cossermelli Messina, W., *et al.* ..... (A) 255
Association of an HLA-DQ allele with clinical tuberculosis. Goldfeld, A. E., *et al.* ..... (A) 294
Association of polymorphism at COL3A and CTLA4 loci on chromosome 2q31–33 with the clinical phenotype and *in vitro* CMI status in healthy and leprosy subjects: a preliminary study. Kaur, G., *et al.* ..... (A) 287
[Atypical cases of leprosy: a two-case study.] Benzekri, L. and Hassam, B. ..... (A) 255
[Bacilloscopic evaluation in Virchowian hanseniasis (study of 60 necropsies.] Trifilo, M. O., *et al.* ..... (A) 503
Cauda equina syndrome masquerading as leprosy. Ramesh, A., *et al.* ..... (A) 258
Cellular reaction to *M. avium* complex (MAC) clinical isolates differing in hemolytic activity and virulence for C57BL/6 mice. Brzychy, M., *et al.* ..... (A) 421
Characterization of rpoB mutations in rifampin-resistant clinical *M. tuberculosis* isolates from Greece. Matsiota Bernard, P., *et al.* ..... (A) 298
Clinical and histopathological activity in paucibacillary leprosy patients after fixed-duration multidrug therapy. Ebenezer, G. J., *et al.* ..... (A) 89
Clinical application of the *M. tuberculosis* direct test: case report, literature review, and proposed clinical algorithm. Gladwin, M. T., *et al.* ..... (A) 521
Clinical correlates of interferon gamma production in patients with tuberculosis. Sodhi, A., *et al.* ..... (A) 119
Cloning and nucleotide sequence of the DNA gyrase gyrA gene from *Serratia marcescens*

and characterization of mutations in gyrA of quinolone-resistant clinical isolates. Kim, J. H., *et al.* ..... (A) 296
Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant *M. tuberculosis* clinical isolates. Segura, C., *et al.* ..... (A) 525
Detection of *M. tuberculosis* by PCR analysis of urine and other clinical samples from AIDS and non-HIV-infected patients. Sechi, L. A., *et al.* ..... (A) 119
Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant *M. tuberculosis*. Gadre, D. V., *et al.* ..... (A) 497
Evaluation of a commercial probe assay for detection of rifampin resistance in *M. tuberculosis* directly from respiratory and nonrespiratory clinical samples. Gamboa, F., *et al.* ..... (A) 521
Genetic variations at the T cell receptor gamma locus in circulating peripheral blood mononuclear cells of clinically categorized leprosy patients. Sachdeva, G., *et al.* ..... (A) 287
Mycobacterial Diseases Part I: Clinical Frontiers, A. Malin and K. P. W. J. McAdam, eds. .. (A) 496
Reverse transcription-PCR detection of *M. leprae* in clinical specimens. Kurabachew, M., *et al.* ..... (A) 415

Clofazimine,
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma. Ruff, P., *et al.* ..... (A) 428
Does clofazimine have a prophylactic role against neuritis? Arunthathi, S. and Satheesh, K. K. ..... (A) 84
Excretion of clofazimine in human milk in leprosy patients. Venkatesan, K., *et al.* ..... (A) 83
Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against *M. avium*. Horgen, L., *et al.* ..... (A) 251

Cloning,
Cloning and expression of an acyl-CoA dehydrogenase from *M. tuberculosis*. Mahadevan, U. and Padmanaban, G. ..... (A) 415
Cloning and nucleotide sequence of the DNA gyrase gyrA gene from *Serratia marcescens* and characterization of mutations in gyrA of quinolone-resistant clinical isolates. Kim, J. H., *et al.* ..... (A) 296
Cloning of the antigen 85A from *M. gordonae* and its use for the specific PCR identification of these mycobacteria. Dumonceaux, M., *et al.* ..... (A) 110
Cloning, sequencing and expression of mig gene of *M. avium*, which codes for a secreted macrophage-induced protein. Plum, G., *et al.* ..... (A) 117
Identification and cloning of the *M. avium* folA gene, required for dihydrofolate reductase activity. Ginkel, S. Z., *et al.* ..... (A) 276
Identification of iron-regulated proteins of *M. tuberculosis* and cloning of tandem genes encoding a low iron-induced protein and a metal transporting ATPase with similarities to two-component metal transport systems. Calder, K. M. and Horwitz, M. A. ..... (A) 421
Identification of mycobacterial HSP70 reactive human T cell clones discriminating between *M. tuberculosis* and *M. leprae*. Oftung, F. and Lundin, K. E. A. ..... (A) 280
Requirement for different presenting cells and for different processing mechanisms by human CD4 T helper clones specific for *M. tuberculosis* antigens. Manca, F., *et al.* ..... (A) 410
Type 1- and type 2-like skin-derived *M. leprae*-responsive T cell clones are characterized by coexpression of IFN-gamma/TNF-alpha and IL-4/IL-5/IL-13, respectively. Verhagen, C. E., *et al.* ..... (A) 271

Complement,
A sequential study of circulating immune complexes, complement and immunoglobulins in borderline tuberculoid leprosy patients with and without reactions. Ramanathan, V. D., *et al.* ..... (A) 507
Involvement of antilipoarabinomannan antibodies in classical complement activation in tuberculosis. Hetland, G., *et al.* ..... (A) 265
Nonopsonic binding of *M. tuberculosis* to complement receptor type 3 is mediated by capsular polysaccharides and is strain dependent. Cywes, C., *et al.* ..... (A) 109

Conferences/Congresses,
8th International Congress on Infectious Diseases ..... (N) 77
10th International Congress of Immunology ..... (N) 245
20th Biennial conference of IAL at Bhopal. Porichha, D. ..... (N) 74
Commemoration of first International Leprosy Congress ..... (N) 72
Fourth Congress of the China Leprosy Association. He, D. ..... (N) 492

Maharashtra State Leprosy Workers' Conference held. Naik, S.S. ..... (N) 245
[The centenary of the International Leprosy Congresses.] Terencio de las Aguas, J. ..... (A) 79
Transactions of the Fifteenth International Leprosy Congress ..... (-) 531
U.S.-Japan Cooperative Medical Science Program, Thirty-Third U.S.-Japan Tuberculosis and Leprosy Research Conference, Osaka, Japan, 8–10 July 1998 ..... (A) 430

Control of leprosy,
A case-control study of the effectiveness of the BCG vaccine for preventing leprosy in Yangon, Myanmar. Bertolli, J., *et al.* ..... (A) 101
Effectiveness of bacillus Calmette-Guerin (BCG) vaccination in the prevention of leprosy; a case-finding control study in Nagpur, India. Zodpey, S. P., *et al.* ..... (O) 309
[Evaluation of the elimination of leprosy in Burkina Faso.] Tiendrebeogo, A., *et al.* ..... (A) 516
Global elimination of leprosy. Gillis, T. P. and Krahenbuhl, J. L. ..... (A) 399
Health systems research in leprosy control—what contributions can it make? Lever, P., *et al.* (A) 496
Leprosy beyond the year 2000. ..... (A) 247
[Leprosy control in Chencen town of Shunde County, Guangdong.] Feng, Z. ..... (A) 502
Leprosy elimination campaigns—reaching every patient in every village. World Health Organization ..... (A) 499
[Leprosy endemic and its control in Yunnan Province.] Xu, K., *et al.* ..... (A) 104
NLEP; utilizing primary health care workers for case detection. Vijayakumaran, P., *et al.* ... (A) 516
[On optimal input of resources for leprosy control after its basic eradication.] Xu, Y., *et al.* .. (A) 79
Progress towards leprosy elimination. World Health Organization ..... (A) 499
[The action of health education on popularizing knowledge of leprosy control.] Wen, Y., *et al.* (A) 248
The dangers of misinterpretation of the elimination campaign. Ross, W. F. ..... (E) 222
The National Leprosy Control Programme of Zimbabwe: a data analysis, 1983–1992. Wittenhorst, B., *et al.* ..... (A) 419
The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987–1995. II. Reactions. Schreuder, P. A. M. ..... (O) 159
The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987–1995. I. Overview of the study. Schreuder, P. A. M. ..... (O) 149
The occurrence of reactions and impairments in leprosy: experience of the leprosy control program of three provinces in northeastern Thailand, 1987–1995. III. Neural and other impairments. Schreuder, P. A. M. ..... (O) 170
Toward the elimination of leprosy: the challenges and opportunities. Noordeen, S. K. ..... (E) 218

Corticosteroids,
Field treatment of acute nerve function impairment in leprosy using a standardized corticosteroid regimen—first year's experience with 100 patients. Croft, R. P., *et al.* ..... (A) 256
Peptic ulcer and corticosteroid therapy. Arunthathi, S., *et al.* ..... (C) 225

Cutaneous,
Dapsone induced pulmonary eosinophilia without cutaneous allergic manifestations—an unusual encounter—a case report. Arunthathi, S. and Raju, S. ..... (A) 497
[Reactivity of cutaneous leprosy lesions to epicutaneous and intradermal immunologic agents.] dos Santos, I. B. and Pereira, A. C., Jr. ..... (A) 265
Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Stevens, R. J., *et al.* ..... (A) 304
Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome—a randomized, double-blind, placebo-controlled trial. Hamuryudan, V., *et al.* ..... (A) 295
Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Or, R., *et al.* ..... (A) 299

Cycloserine,
Overexpression of the D-ananine racemase gene confers resistance to D-cycloserine in *M. smegmatis*. Caceres, N. E., *et al.* ..... (A) 108

Cytokines,
Cytokine patterns in tubeculosis and sarcoid granulomas—correlations with histopathologic features of the granulomatous response. Bergeron, A., *et al.* ..... (A) 87

Expression and cytokine secretion in the states of immune reactivation in leprosy. Sampaio, E. P. and Sarno, E. N. ..... (A) 169
Role of cytokines in the pathogenesis of erythema nodosum leprosum. Kaplan, G. ..... (A) 433

Dapsone (DDS),
[A case of leprosy hypersensitive to both DDS and RMP.] Cui, L. ..... (A) 285
Antiinflammatory action of dapsone: inhibition of chemoattractant-induced signal transduction. Debol, S. M., *et al.* ..... (A) 291
Comparison of the *in vitro* cytotoxicity of hydroxylamine metabolites of sulfamethoxazole and dapsone. Reilly, T. P., *et al.* ..... (A) 252
Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. Tingle, M. D., *et al.* ..... (A) 253
Dapsone hydroxylamine inhibits the LTB4-induced chemotaxis of polymorphonuclear leukocytes into human skin: results of a pilot study. Wozel, G., *et al.* ..... (A) 83
Dapsone induced pulmonary eosinophilia without cutaneous allergic manifestations—an unusual encounter—a case report. Arunthathi, S. and Raju, S. ..... (A) 497
[Effect of oral DDS for prevention of leprosy.] Yang, X., *et al.* ..... (A) 104
[Effects of retreatment with MDT in persons cured of leprosy by using DDS monotherapy.] Mao, Q., *et al.* ..... (A) 498
[Effects of retreatment with MDT on 472 persons cured of leprosy with DDS monotherapy.] Wang, J., *et al.* ..... (A) 254
Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients. Queiroz, R. H. C., *et al.* ..... (A) 82
Molecular modeling study on dapsone and sulfonamides comparing structures and properties with respect to antileprosy activity. Scior, T., *et al.* ..... (A) 82
Multidrug-resistance to dapsone, rifampicin, and ofloxacin in *M. leprae*. Cambau, E., *et al.* .. (A) 249
Neuroprotective effect of dapsone against quinolinate- and kainate-induced striatal neurotoxicities in rats. Santamaria, A., *et al.* ..... (A) 301
Penetration of dapsone into cerebrospinal fluid of patients with AIDS. Gatti, G., *et al.* ..... (A) 110

Deformity, disability,
[Changes of disability in 240 persons cured of leprosy.] Wang, H., *et al.* ..... (A) 253
[Disability among 1522 cases of leprosy using MDT.] Dan, Z., *et al.* ..... (A) 105
Impairment and disability in leprosy: in search of the missing link. van Brakel, W. H. and Anderson, A. M. ..... (A) 289
Leprosy disabilities: the impact of multidrug therapy (MDT). Ladhani, S. ..... (A) 498
The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987–1995. II. Reactions. Schreuder, P. A. M. ..... (O) 159
The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987–1995. I. Overview of the study. Schreuder, P. A. M. ..... (O) 149
The occurrence of reactions and impairments in leprosy: experience of the leprosy control program of three provinces in northeastern Thailand, 1987–1995. III. Neural and other impairments. Schreuder, P. A. M. ..... (O) 170
The impact of multiple drug therapy on leprosy disabilities. Willcox, M. L. ..... (A) 254
The prevalence of disabling ocular complications of leprosy: a global study. ffytche, T. J. ... (A) 403

Dehydrogenase,
Cloning and expression of an acyl-CoA dehydrogenase from *M. tuberculosis*. Mahadevan, U. and Padmanaban, G. ..... (A) 415
NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in *M. smegmatis*. Miesel, L., *et al.* ..... (A) 426

Dermal,
A case of lymphocytic vasculitis with infiltration of dermal nerves resembling indeterminate leprosy. Job, C. K., *et al.* ..... (E) 49
Atypical post-kala-azar dermal leishmaniasis resembling histoid leprosy. Chakrabarti, A., *et al.* ..... (A) 84
[Reactivity of cutaneous leprosy lesions to epicutaneous and intradermal immunologic agents.] dos Santos, I. B. and Pereira, A. C., Jr. ..... (A) 265

DNA,
Cloning and nucleotide sequence of the DNA gyrase gyrA gene from *Serratia marcescens* and characterization of mutations in gyrA of quinolone-resistant clinical isolates. Kim, J. H., *et al.* ..... (A) 296
Comparison of the ABI 7700 system (TaqMan) and competitive PCR for quantification of IS6110 DNA in sputum during treatment of tuberculosis. Desjardin, L. E., *et al.* ..... (A) 520
DNA amplification for detection of leprosy and assessment of efficacy of leprosy chemotherapy. Kampirapap, K., *et al.* ..... (O) 16
DNA vaccines against tuberculosis. Lowrie, D. B., *et al.* ..... (A) 267
Development of mycobacterial species-specific DNA probes by subtraction hybridization. Hughes, M. S., *et al.* ..... (A) 278
[Establishment of high-potent genome DNA library of *M. leprae* and its evaluation.] Yin, Y., *et al.* ..... (A) 513
Genetic diversity in the *M. tuberculosis* complex based on variable numbers of tandem DNA repeats. Frothingham, R. and Meeker-O'Connell, W. A. ..... (A) 424
Identification and characterization of protective T cells in hsp 65 DNA-vaccinated and *M. tuberculosis*-infected mice. Bonato, V. L. D., *et al.* ..... (A) 263
Identification of potential CD8+ T-cell epitopes of the 19 kDa and AhpC proteins from *M. tuberculosis*. No evidence for CD8+ T-cell priming against the identified peptides after DNA-vaccination of mice. Erb, K. J., *et al.* ..... (A) 423
SOS induction in mycobacteria: analysis of the DNA-binding activity of a LexA-like repressor and its role in DNA damage induction of the recA gene from *M. smegmatis*. Durbach, S. I., *et al.* ..... (A) 95
[The multiplex polymerase chain reaction assay for the detection of *M. paratuberculosis* DNA in Crohn's disease tissue.] Al Shamali, M., *et al.* ..... (A) 107
Vaccination with plasmid DNA encoding mycobacterial antigen 85 stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by *M. tuberculosis* H37Rv infection. Denis, O., *et al.* ..... (A) 422

Drugs (see also **Multidrug therapy** and specific drugs),
A rapid drug susceptibility test for *M. tuberculosis* using the hybridization protection assay. Koga, H., *et al.* ..... (A) 113
Conditionally replicating luciferase reporter phages: improved sensitivity for rapid detection and assessment of drug susceptibility of *M. tuberculosis*. Carriere, C., *et al.* ..... (A) 274
Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant *M. tuberculosis* clinical isolates. Segura, C., *et al.* ..... (A) 525
[Effect of prednisone on silent neuritis in leprosy.] Zhou, L., *et al.* ..... (A) 407
Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant *M. tuberculosis*. Gadre, D. V., *et al.* ..... (A) 497
In vitro activity of fluorinated quinolones and macrolides against drug-resistant *M. tuberculosis*. Hoffner, S. E., *et al.* ..... (A) 296
Minimal inhibitory concentrations of sulbactam/ampicillin against drug sensitive and drug resistant isolates of *M. tuberculosis*. Paramasivan, C. N., *et al.* ..... (A) 116
Molecular beacon sequence analysis for detecting drug resistance in *M. tuberculosis*. Piatek, A. S., *et al.* ..... (A) 427
Multidrug-resistance to dapsone, rifampicin, and ofloxacin in *M. leprae*. Cambau, E., *et al.* .. (A) 249
Sparfloxacin in the treatment of leprosy patients. Ishi, N., *et al.* ..... (A) 497
Synergistic activities of antituberculous drugs with cerulenin and trans-cinnamic acid against *M. tuberculosis*. Rastogi, N., *et al.* ..... (A) 524
The clinical use of fluoroquinolones for the treatment of mycobacteria. Alangaden, G. J. and Lerner, S. A. ..... (A) 248
Trends in drug-resistant tuberculosis in the United States, 1993–1996. Moore, M., *et al.* .... (A) 114
Update on rifampin drug interactions. Strayhorn, V. A., *et al.* ..... (A) 253

ELISA (enzyme-linked immunosorbent assay),
[A study of the sensitivity and specificity of the anti-PGL-I ELISA.] Brasil, M. T. L.R. F., *et al.* ..... (A) 504

Enzyme(s),
Extracellular enzyme activities potentially involved in the pathogenicity of *M. tuberculosis*. Raynaud, C., *et al.* ..... (A) 281

Epidemiology,
An epidemic of tuberculosis with a high rate of tuberculin energy among a population previously unexposed to tuberculosis, the Yanomami Indians of the Brazilian Amazon. Sousa, A. O., *et al.* ..... (A) 303
An epidemiological study of *M. leprae* infection and prevalence of leprosy in an endemic district of North Maluku, Indonesia. Izumi, S., *et al.* ..... (A) 433
[Analysis of 87 newly detected cases of leprosy for the past 12 years.] Song, X., *et al.* ..... (A) 515
Decreased survival of HTLV-I carriers in leprosy patients from the Democratic Republic of the Congo: a historical prospective study. Lechat, M. F., *et al.* ..... (A) 102
Epidemiological aspects of ocular morbidity in leprosy affected persons. Sundar Rao, P. S. S., *et al.* ..... (A) 405
[Epidemiological evaluation of a group of leprosy patients diagnosed in 1996.] Castellazi, Z., *et al.* ..... (A) 284
Epidemiological significance of first skin lesion in leprosy. Abraham, S., *et al.* ..... (O) 131
[Estimated prevalence of leprosy.] Gil Suarez, R. E. and Lombardi, C. ..... (A) 514
Global case detection trend in leprosy. World Health Organization. ..... (A) 516
Hidden cases of leprosy (in prison). Vijayakumaran, P., *et al.* ..... (A) 286
[Integration of vertical system and general medical services for case-finding in leprosy.] Yang, J., *et al.* ..... (A) 104
[Leprosy and climate.] Niu, S., *et al.* ..... (A) 515
Leprosy and tuberculosis: the epidemiological consequences of cross-immunity. Lietman, T., *et al.* ..... (A) 285
Leprosy in the balance—predicting the future. Smith, C. ..... (A) 515
[Method of detection and source of infection in the incidence of leprosy.] Ferra Torres, T. and Carrazana Hernandez, G. B. ..... (A) 102
[On correlation between health education and early case finding in leprosy.] Wen, Y., *et al.* .. (A) 419
Studies on rapid assessment methods in leprosy. Gupte, M. D., *et al.* ..... (A) 514
[Study on the recent trends of leprosy epidemiology in Yangzhou Prefecture and Dongtai City, Jiangsu Province.] Shen, J., *et al.* ..... (A) 104
The epidemiology of ocular complications of leprosy. Courtright, P. ..... (A) 402

Erythema nodosum leprosum (ENL),
Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Moreira, A. L., *et al.* ..... (C) 61
Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum. Rea, T. H. and Sieling, P. A. ..... (O) 316
IgM anti-phenolic glycolipid I and IgG anti-10-kDa heat shock protein antibodies in sera and immune complexes isolated from leprosy patients with or without erythema nodosum leprosum and contacts. Rojas, R. E., *et al.* ..... (A) 92
Pentoxifylline decreases *in vivo* and *in vitro* tumour necrosis factor-alpha production in lepromatous leprosy patients with erythema nodosum leprosum. Sampaio, E. P., *et al.* ..... (A) 269
Role of cytokines in the pathogenesis of ENL. Kaplan, G. ..... (A) 433
The management of erythema nodosum leprosum: current and future options. Lockwood, D. N. J. ..... (A) 85

Escherichia coli,
Immunological characterization of five recombinant *M. leprae* proteins produced in *Escherichia coli.* Suzuki, Y., *et al.* ..... (A) 437

Ethambutol,
A single point mutation in the embB gene is responsible for resistance to ethambutol in *M. smegmatis*. Lety, M. A., *et al.* ..... (A) 279
Flow cytometric testing of susceptibilities of *M. tuberculosis* isolates to ethambutol, isoniazid, and rifampin in 24 hours. Kirk, S. M., *et al.* ..... (A) 425
Role of embB in natural and acquired resistance to ethambutol in mycobacteria. Alcaide, F., *et al.* ..... (A) 94

Ethiopia,
ALERT 1999 Training Calendar ..... (N) 395
Delay in presentation and start of treatment in leprosy patients: a case-control study of disabled and non-disabled patients in three different settings in Ethiopia. Bekri, W., *et al.* ... (O) 1

Progress in research towards a world without leprosy. Report of a WHO meeting in Ethiopia. Roche, P., *et al.* ..... (A) 497

Eye(s),
[A survey of the oculopathy in 1897 cases of leprosy.] Wang, B., *et al.* ..... (A) 503
Abnormal capillary proliferation in the iris of a leprosy patient. Ebenezer, G. J., *et al.* ..... (C) 58
Assessment and treatment of the dry eye in leprosy. Passerotti, S., *et al.* ..... (A) 405
Bilateral iridocyclitis caused by *M. leprae* diagnosed through paracentesis. Campos, W. R., *et al.* ..... (A) 402
[Changes in the cornea and of vision in leprosy patients.] Tang, X. ..... (A) 503
[Corneal lesions in 228 leprosy patients.] Yan, L., *et al.* ..... (A) 86
Corneal ulcer caused by *Nocardia asteroides* in a patient with leprosy. Tendolkar, U. M., *et al.* (A) 260
Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin and ethambutal for *M. avium* complex bacteremia: a multivariate analysis. Shafran, S. D., *et al.* ..... (A) 302
Epidemiological aspects of ocular morbidity in leprosy affected persons. Sundar Rao, P. S. S., *et al.* ..... (A) 405
Extracapsular cataract extraction and intraocular lens implantation in leprosy patients: visual outcome and complications. Batistella, G. G. G., *et al.* ..... (A) 401
Histopathological features of lepromatous iridocyclitis; a case report. Job, C. K. and Thompson, K. ..... (O) 29
Immunotherapy of uveitis. Biswas, J. and Raizada, S. ..... (A) 402
Lagophthalmos in leprosy. Daniel, E. ..... (A) 403
Longitudinal follow up of eyes in leprosy. Rajan, M. A. ..... (A) 405
Ocular impairments in an impairment survey of leprosy-affected persons in Nepal. Knuuttila, J. P., *et al.* ..... (A) 404
Ocular morbidity in a sample of 150 treated leprosy patients. Thompson, K. ..... (A) 405
Pathology of eye in leprosy. Job, C. K., *et al.* ..... (A) 404
Present situation of eye care and research in leprosy in China. Yao, J. and Qian, J. ..... (A) 406
Strategies for improvement of management of ocular complications in leprosy. Hogeweg, M. (A) 403
Study of ocular changes in leprosy patients. Monteiro, L. G., *et al.* ..... (A) 502
Surgical treatment of secondary cataract in leprosy. Yao, J. and Qian, J. ..... (A) 407
The antimicrobial susceptibility of *M. chelonae* isolated from corneal ulcer. Hu, F. R., *et al.* .. (A) 112
The challenge: organizing services to prevent blindness in leprosy patients. Waddell, K. .... (A) 406
The current situation of lagophthalmos and keratopathy of leprosy in PR China. Jiang, J. and Wei, X. Y. ..... (A) 404
The epidemiology of ocular complications of leprosy. Courtright, P. ..... (A) 402
The prevalence of disabling ocular complications of leprosy: a global study. ffytche, T. J. ... (A) 403

Face,
Correlation of oral surface temperatures and the lesions of leprosy. Scheepers, A. ..... (O) 214
Quantitative assessment of facial sensation in leprosy. Premkumar, R., *et al.* ..... (O) 348

Family,
A controlled study of the influence of segregation of tuberculous patients for 1 year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Kamat, S. R., *et al.* ..... (A) 522
Genetics of host resistance and susceptibility to intramacrophage pathogens: a study of multicase families of tuberculosis, leprosy and leishmaniasis in northeastern Brazil. Blackwell, J. M. ..... (A) 262
Immunogenetics of leishmanial and mycobacterial infections: the Belem family study. Blackwell, J. M., *et al.* ..... (A) 88

Feline leprosy,
Determination of the etiology of presumptive feline leprosy by 16S rRNA gene analysis. Hughes, M. S., *et al.* ..... (A) 112

Finger(s),
Application of "measured tension" technique in correction of claw fingers by tendon transfer in leprosy. Sane, S. B., *et al.* ..... (A) 288
Joshi external stabilizing system (JESS) in proximal interphalangeal joint (PIP) contractures in leprosy. Salafia, A. and Chauhan, G. ..... (A) 288
Unfavorable results after surgical correction of claw fingers in leprosy. Malaviya, G. N. .... (A) 287

Foot,
[Anesthesia of hands and feet in 152 disabled leprosy patients.] Zhang, L., *et al.* ..... (A) 289
[Effect of protective footwear on plantar ulcers.] Ma, J. ..... (A) 106
[Effects of protective footwear on preventing plantar ulcer.] Zhu, Z., *et al.* ..... (A) 290

Foot pad(s),
Inhibition of multiplication of *M. leprae* in mouse foot pads by immunization with ribosomal fraction and culture filtrate from *M. bovis* BCG. Matsuoka, M., *et al.* ..... (A) 100
Viability determination of *M. leprae*: comparison of normal mouse foot pad and bacillary ATP bioluminescence assay. Gupta, U. D., *et al.* ..... (A) 277

France,
ALLF second bulletin published ..... (N) 72

Genetics,
Expression of a gene for a porin-like protein OmpA family from *M. tuberculosis* H37Rv. Senaratne, R. H., *et al.* ..... (A) 525
Expression systems for study of mycobacterial gene regulation and development of recombinant BCG vaccines. DasGupta, S. K., *et al.* ..... (A) 520
Genetic diversity in the *M. tuberculosis* complex based on variable numbers of tandem DNA repeats. Frothingham, R. and Meeker-O'Connell, W. A. ..... (A) 424
Genetic vaccination against tuberculosis. Lowrie, D. B., *et al.* ..... (A) 297
Genetic variations at the T cell receptor gamma locus in circulating peripheral blood mononuclear cells of clinically categorized leprosy patients. Sachdeva, G., *et al.* ..... (A) 287
Genetics of host resistance and susceptibility to intramacrophage pathogens: a study of multicase families of tuberculosis, leprosy and leishmaniasis in northeastern Brazil. Blackwell, J. M. ..... (A) 262
Identification of genetic loci implicated in the survival of *M. smegmatis* in human mononuclear phagocytes. Lagier, B., *et al.* ..... (A) 511
Immunogenetics of leishmanial and mycobacterial infections: the Belem family study. Blackwell, J. M., *et al.* ..... (A) 88
Intractable mycobacterial infections associated with genetic defects in the receptor for interferon gamma: what does this tell us about immunity to mycobacteria? Rook, G. A. W. .... (A) 93
Mycobacteriophage L5 infection of *M. bovis* BCG: implications for phage genetics in the slow-growing mycobacteria. Fullner, K. J. and Hatfull, G. F. ..... (A) 96
Susceptibility to leprosy is linked to the human NRAMP1 gene. Abel, L., *et al.* ..... (A) 284

Genome,
Deciphering the biology of *M. tuberculosis* from the complete genome sequence. Cole, S. T., *et al.* ..... (A) 520
[Establishment of high-potent genome DNA library of *M. leprae* and its evaluation.] Yin, Y., *et al.* ..... (A) 513
Multiplex sequencing of 1.5 Mb of the *M. leprae* genome. Smith, D. R., *et al.* ..... (A) 99
Mycobacterial genome structure—minireview. Philipp, W. J., *et al.* ..... (A) 416
Use of a *M. tuberculosis* H37Rv bacterial artifical chromosome library for genome mapping, sequencing, and comparative genomics. Brosch, R., *et al.* ..... (A) 413

Germany,
Commemoration of first International Leprosy Congress ..... (N) 72
Leprosy type 1 reaction as the first manifestation of borderline lepromatous leprosy in a young native German. Biedermann, T., *et al.* ..... (A) 401

Granuloma(s),
A role for granulomatous inflammation in the transmission of infectious disease: schistosomiasis and tuberculosis. Doenhoff, M. J. ..... (A) 422
Adequate expression of protective immunity in the absence of granuloma formation in *M. tuberculosis*-infected mice with a disruption in the intracellular adhesion molecule 1 gene. Johnson, C. M., *et al.* ..... (A) 425
Cytokine patterns in tuberculosis and sarcoid granulomas— correlations with histopathologic features of the granulomatous response. Bergeron, A., *et al.* ..... (A) 87
Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-gamma and IL-4 knockout mice—analysis of local and regional cytokine and chemokine networks Chensue, S. W., *et al.* ..... (A) 88

T-cell-independent granuloma formation in response to *M. avium*: role of tumour necrosis factor-alpha and interferon gamma. Smith, D., *et al.* ..... (A) 270
Why relapse occurs in PB leprosy patients after adequate MDT despite they are Mitsuda reactive: lessons from Convit's experiment on bacteria-clearing capacity of lepromin-induced granuloma. Chaudhuri, S., *et al.* ..... (O) 182

Greece,
Characterization of rpoB mutations in rifampin-resistant clinical *M. tuberculosis* isolates from Greece. Matsiota Bernard, P., *et al.* ..... (A) 298

Hand(s),
[Anesthesia of hands and feet in 152 disabled leprosy patients.] Zhang, L., *et al.* ..... (A) 289
Restoration of abduction-opposition in paralyzed thumb in leprosy. Sane, S. B., *et al.* ..... (A) 288
[Surgical correction of clawhand in leprosy.] Wang, J., *et al.* ..... (A) 420
The metacarpophalangeal stabilization test: its surgical interest. Bourrel, P. ..... (A) 286
Wrist involvement in Hansen's disease. Carpintero, P., *et al.* ..... (A) 105

Histoid leprosy,
Atypical post-kala-azar dermal leishmaniasis resembling histoid leprosy. Chakrabarti, A., *et al.* (A) 84
Giant lesions in histoid leprosy. Ramesh, V., *et al.* ..... (C) 232

Histopathology,
Clinical and histopathological activity in paucibacillary leprosy patients after fixed-duration multidrug therapy. Ebenezer, G. J., *et al.* ..... (A) 89
Cytokine patterns in tuberculosis and sarcoid granulomas— correlations with histopathologic features of the granulomatous response. Bergeron, A., *et al.* ..... (A) 87
[Histopathological feature of type 2 reaction in leprosy.] Wu, Y., *et al.* ..... (A) 406
[Histopathological features five years after MDT in 572 cases of MB leprosy.] Wang, Y., *et al.* (A) 83
Histopathological features of lepromatous iridocyclitis; a case report. Job, C. K. and Thompson, K. ..... (O) 29
The nose in leprosy: immunohistology of the nasal mucosa. Fokkens, W. J., *et al.* ..... (O) 328

History of leprosy,
Anti-Contagionism in leprosy, 1844-1897. Pandya, S. S. ..... (E) 374
[Leprosy—current aspects.] Stitch-Groh, V. and Bretzel, G. ..... (A) 399
Leprosy Minutiae by Rajiv Joshi. Hastings, R. C. ..... (B) 489
Leprosy research and patient care over the past century. Meyers, W. M. ..... (E) 43
Women and leprosy: a review. Le Grand, A. ..... (A) 79

HLA (see also **Genetics**),
Association of HLA-class I antigens and haplotypes with relapse or pulmonary tuberculosis in patients treated with short course chemotherapy. Selvaraj, P., *et al.* ..... (A) 301
Association of an HLA-DQ allele with clinical tuberculosis. Goldfeld, A. E., *et al.* ..... (A) 294

Human immunodeficiency virus (HIV),
A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. Marriott, J. B., *et al.* ..... (A) 298
[Antibody to HIV-1 in the sera of leprosy patients.] Chan, J., *et al.* ..... (A) 85
Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to *M. avium*. May, T., *et al.* .... (A) 114
Concurrent leprosy and HIV infection: a report of three cases. Sayal, S. K., *et al.* ..... (A) 258
Cytokine networks with infection: mycobacterial infections, leishmaniasis, human immunodeficiency virus infection, and sepsis. Dipiro, J. T. ..... (A) 265
Detection of *M. tuberculosis* by PCR analysis of urine and other clinical samples from AIDS and non-HIV-infected patients. Sechi, L. A., *et al.* ..... (A) 119
Leprosy and HIV infection in Bahia, Brazil. Machado, P., *et al.* ..... (C) 227
Monocytes modulate enhancement of HIV-I replication by *M. tuberculosis*. De Hass, C. J. C., *et al.* ..... (A) 264
Reversal reaction, nerve damage and steroid therapy in three multibacillary HIV positive patients. Arunthathi, S., *et al.* ..... (A) 500
Survival of HIV-positive and HIV-negative leprosy patients in Mwanza, Tanzania. van den Broek, J., *et al.* ..... (C) 53

The *in vitro* induction of human immunodeficiency virus (HIV) replication in PPD-positive HIV-infected persons by recall antigen response to *M. tuberculosis* is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. Goletti, D., *et al.* ..... (A) 424
The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. Haslett, P., *et al.* ..... (A) 111

Hypersensitivity,
Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum. Rea, T. H. and Sieling, P. A. ..... (O) 316

ILEP (International Federation of Anti-Leprosy Associations),
"Sustaining leprosy Related Activities—Guidelines for Responding to Change"—new ILEP publication ..... (N) 77

Immune complexes,
A sequential study of circulating immune complexes, complement and immunoglobulins in borderline tuberculoid leprosy patients with and without reactions. Ramanathan, V. D., *et al.* ..... (A) 507
IgM anti-phenolic glycolipid I and IgG anti-10-kDa heat shock protein antibodies in sera and immune complexes isolated from leprosy patients with or without erythema nodosum leprosum and contacts. Rojas, R. E., *et al.* ..... (A) 92

Immune responses,
Cellular immune responses of healthy and *M. leprae*-inoculated armadillos (*Dasypus novemcinctus*). Rivero-Nava, L., *et al.* ..... (C) 485
Regulation of the human immune response during tuberculosis. Ellner, J. J. ..... (A) 293

Immunoglobulins,
A sequential study of circulating immune complexes, complement and immunoglobulins in borderline tuberculoid leprosy patients with and without reactions. Ramanathan, V. D., *et al.* ..... (A) 507
IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type 2 lepra reaction on thalidomide treatment. Partida Sanchez, S., *et al.* ..... (A) 507
IgG subclass distribution of antibody responses to protein and polysaccharide mycobacterial antigens in leprosy and tuberculosis patients. Sousa, A. O., *et al.* ..... (A) 270
IgM anti-phenolic glycolipid I and IgG anti-10-kDa heat shock protein antibodies in sera and immune complexes isolated from leprosy patients with or without erythema nodosum leprosum and contacts. Rojas, R. E., *et al.* ..... (A) 92
Levels of IgG subclasses in active and inactive cases in the disease spectrum of leprosy. Beuria, M. K., *et al.* ..... (A) 262
Tumor necrosis factor alpha, interleukin-1-beta and immunoglobulin (GM and KM) polymorphisms in leprosy—a linkage study. Levee, G., *et al.* ..... (A) 285

Immunology,
10th International Congress of Immunology ..... (N) 245
Immunological characterization of five recombinant *M. leprae* proteins produced in *Escherichia coli*. Suzuki, Y., *et al.* ..... (A) 437
Immunological requirements for a subunit vaccine against tuberculosis. El Hay, M. J. and Andersen, P. ..... (A) 423
[Reactivity of cutaneous leprosy lesions to epicutaneous and intradermal immunologic agents.] dos Santos, I. B. and Pereira, A. C., Jr. ..... (A) 265
Recombinant interleukin-2 in lepromatous leprosy lesions: immunological and microbiological consequences. Villahermosa, L. G., *et al.* ..... (A) 509
The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. Haslett, P., *et al.* ..... (A) 111

Immunosuppression,
Potential role of B7-1 and CD28 molecules in immunosuppression in leprosy. Agrewala, J. N., *et al.* ..... (A) 260

Immunotherapy,
Immunotherapy of uveitis. Biswas, J. and Raizada, S. ..... (A) 402

Rational basis of interleukin-12 immunotherapy for established mycobacterial infection in mice. Kobayashi, K., *et al.* ..... (A) 434

Indeterminate leprosy,

A case of lymphocytic vasculitis with infiltration of dermal nerves resembling indeterminate leprosy. Job, C. K., *et al.* ..... (E) 49

India,

20th Biennial conference of IAL at Bhopal. Porichha, D. ..... (N) 74
10th International Congress of Immunology ..... (N) 245
1998 SLR&TC Karigiri course schedule ..... (N) 72
1999 Schieffelin leprosy courses at Karigiri ..... (N) 493
A controlled study of the influence of segregation of tuberculous patients for 1 year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Kamat, S. R., *et al.* ..... (A) 522
Data utilization and analytical skills among NLEP managers. Rao, P. S., *et al.* ..... (A) 248
Diffuse alopecia of the scalp in borderline lepromatous leprosy in an Indian patient. Abraham, S., *et al.* ..... (A) 254
Double jeopardy: women and leprosy in India. Vlassoff, C., *et al.* ..... (A) 289
Effectiveness of bacillus Calmette-Guerin (BCG) vaccination in the prevention of leprosy; a case-finding control study in Nagpur, India. Zodpey, S. P., *et al.* ..... (O) 309
Hidden sources of infection in unapproachable areas. Rajdekar, M. P., *et al.* ..... (A) 103
IAL elects new officers. Porichha, D. ..... (N) 75
Maharashtra State Leprosy Workers' Conference held. Naik, S. S. ..... (N) 245
NLEP; utilizing primary health care workers for case detection. Vijayakumaran, P., *et al.* ... (A) 516
Training for the handicapped in photography by VRC ..... (N) 76

Indonesia,

An epidemiological study of *M. leprae* infection and prevalence of leprosy in an endemic district of North Maluku, Indonesia. Izumi, S., *et al.* ..... (A) 433

Interferon,

Clinical correlates of interferon gamma production in patients with tuberculosis. Sodhi, A., *et al.* ..... (A) 119
Differential potentiation of antimycobacterial activity and reactive nitrogen intermediate-producing ability of murine peritoneal macrophages actived by interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha). Sato, K., *et al.* ..... (A) 410
Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for *M. tuberculosis*. Lalvani, T., *et al.* ..... (A) 297
IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type 2 lepra reaction on thalidomide treatment. Partida Sanchez, S., *et al.* ..... (A) 507
Induction of gamma interferon production in human alveolar macrophages by *M. tuberculosis*. Fenton, M. J., *et al.* ..... (A) 294
Induction of *in vitro* human macrophage anti-*M. tuberculosis* activity: requirement for IFN-gamma and primed lymphocytes. Bonecini Almedia, M. G., *et al.* ..... (A) 421
Intractable mycobacterial infections associated with genetic defects in the receptor for interferon gamma: what does this tell us about immunity to mycobacteria? Rook, G. A. W. .... (A) 93
Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-gamma and IL-4 knockout mice—analysis of local and regional cytokine and chemokine networks. Chensue, S. W., *et al.* ..... (A) 88
Production of host-protective (IFN gamma), host-impairing (IL- 10, IL-13) and inflammatory (TNF alpha) cytokines by PMBC from leprosy patients stimulated with mycobacterial antigens. Machado, P., *et al.* ..... (A) 409
Rare transcripts of interferon-gamma detected in lepromatous leprosy cases. Kaur, G., *et al.* .. (C) 65
Susceptibility to *M. leprae* of ALY (alymphoplasia) mice and IFN-gamma induction in the culture supernatant of spleen cells. Yogi, Y., *et al.* ..... (O) 464
T-cell-independent granuloma formation in response to *M. avium*: role of tumour necrosis factor-alpha and interferon gamma. Smith, D., *et al.* ..... (A) 270
Type 1- and type 2-like skin-derived *M. leprae*-responsive T cell clones are characterized by coexpression of IFN gamma/TNF-alpha and IL-4/IL-5/IL-13, respectively. Verhagen, C. E., *et al.* ..... (A) 271

Interleukin(s),
Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Altare, F., *et al.* ..... (A) 407
Inhibition of IL-12 production by thalidomide. Moller, D. R., *et al.* ..... (A) 299
Lethal tuberculosis in interleukin-6-deficient mutant mice. Ladel, C. H., *et al.* ..... (A) 91
Production of host-protective (IFN gamma), host-impairing (IL-10, IL-13) and inflammatory (TNF alpha) cytokines by PMBC from leprosy patients stimulated with mycobacterial antigens. Machado, P., *et al.* ..... (A) 409
Rational basis of interleukin-12 immunotherapy for established mycobacterial infection in mice. Kobayashi, K., *et al.* ..... (A) 434
Recombinant interleukin-2 in lepromatous leprosy lesions: immunological and microbiological consequences. Villahermosa, L. G., *et al.* ..... (A) 509
Roles of IL-18 and IL-12 in the defense mechanism against bacterial infection. Okamura, H. and Nomaguchi, H. ..... (A) 436
Severe mycobacterial and *Salmonella* infections in interleukin 12 receptor-deficient patients. de Jong, R., *et al.* ..... (A) 408
The *in vitro* induction of human immunodeficiency virus (HIV) replication in PPD-positive HIV-infected persons by recall antigen response to *M. tuberculosis* is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. Goletti, D., *et al.* ..... (A) 424
Tumor necrosis factor alpha, interleukin-1-beta and immunoglobulin (GM and KM) polymorphisms in leprosy—a linkage study. Levee, G., *et al.* ..... (A) 285
Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis. Juffermans, N. P., *et al.* ..... (A) 425
Type 1- and type 2-like skin-derived *M. leprae*-responsive T cell clones are characterized by coexpression of IFN-gamma/TNF-alpha and IL-4/IL-5/IL-13, respectively. Verhagen, C. E., *et al.* ..... (A) 271

International Journal of Leprosy (IJL),
Reviewers ..... (-) 528
Statement of Financial Condition ..... (-) 440
Statement of Ownership, Management and Circulation ..... (-) 529

Isoniazid,
Flow cytometric testing of susceptibilities of *M. tuberculosis* isolates to ethambutol, isoniazid, and rifampin in 24 hours. Kirk, S. M., *et al.* ..... (A) 425
Mechanisms involved in the intrinsic isoniazid resistance of *M. avium.* Mdluli, K., *et al.* .... (A) 415
NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in *M. smegmatis*. Miesel, L., *et al.* ..... (A) 426

Japan,
Prevalence of HTLV-I in leprosy patients in two sanatoriums in Japan. Muneishi, H., *et al.* .. (A) 258
[Synthesis of promin in Japan and global elimination of Hansen's disease.] Yuasa, Y. ..... (A) 248
U.S.-Japan Cooperative Medical Science Program, Thirty-Third U.S.-Japan Tuberculosis and Leprosy Research Conference, Osaka, Japan, 8–10 July 1998 ..... (A) 430

Kidney(s),
[Hansen's disease and nephropathy as its sequence.] Matsuo, E., *et al.* ..... (A) 410
Leprosy and renal transplantation. Date, A., *et al.* ..... (A) 403

Korea,
Dietary habits, food intake and functional outcomes in those with a history of Hansen's disease in Korea. Oh, S.-Y., et *al.* ..... (O) 34
Excess mortality associated with blindness in leprosy patients in Korea. Courtright, P., *et al.* (A) 256

Leg(s),
Hemicorporal distribution of lepromatous leprosy in a patient with hemiplegia. Conjo-Mir, J. S., *et al.* ..... (A) 501

Leishmaniasis,
Atypical post-kala-azar dermal leishmaniasis resembling histoid leprosy. Chakrabarti, A., *et al.* (A) 84
Cytokine networks with infection: mycobacterial infections, leishmaniasis, human immunodeficiency virus infection, and sepsis. Dipiro, J. T. ..... (A) 265

Genetics of host resistance and susceptibility to intramacrophage pathogens: a study of multicase families of tuberculosis, leprosy and leishmaniasis in northeastern Brazil. Blackwell, J. M. ..... (A) 262

Lepromatous leprosy,
Chromoblastomycosis simulating lepromatous leprosy. Pavithran, K. ..... (C) 59
Computed tomographic study of paranasal sinuses in lepromatous leprosy. Sharma, V. K., *et al.* ..... (O) 201
Fine-needle aspiration cytology of lepromatous leprosy. Singh, N., *et al.* ..... (A) 508
Fractionation, characterization and diagnostic potential of circulating leprosy antigens isolated from sera of lepromatous leprosy patients. Narayan, R., *et al.* ..... (O) 22
Hemicorporal distribution of lepromatous leprosy in a patient with hemiplegia. Conjo-Mir, J. S., *et al.* ..... (A) 501
High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Ji, B., *et al.* ..... (A) 81
Intranasal anaesthesia in lepromatous leprosy. Soni, N. K. ..... (A) 260
[Onychromycosis and intea pedis caused by *Microsporum nanum* in a patient with lepromatous leprosy.] Sampaio, R. N. R., *et al.* ..... (A) 258
Pentoxifylline decreases *in vivo* and *in vitro* tumour necrosis factor-alpha production in lepromatous leprosy patients with erythema nodosum leprosum. Sampaio, E. P., *et al.* ..... (A) 269
Presence of *M. leprae* in the conjunctiva, vitreous body and retina of a patient having lepromatous leprosy. Orefice, F., *et al.* ..... (A) 404
Rare transcripts of interferon-gamma detected in lepromatous leprosy cases. Kaur, G., *et al.* .. (C) 65
Recombinant interleukin-2 in lepromatous leprosy lesions: immunological and microbiological consequences. Villahermosa, L. G., *et al.* ..... (A) 509
Tumor necrosis factor promote polymorphism and susceptibility to lepromatous leprosy. Roy, S., *et al.* ..... (A) 93

Lepromin,
Why relapse occurs in PB leprosy patients after adequate MDT despite they are Mitsuda reactive: lessons from Convit's experiment on bacteria-clearing capacity of lepromin-induced granuloma. Chaudhuri, S., *et al.* ..... (O) 182

Lesion(s),
[Corneal lesions in 228 leprosy patients.] Yan, L., *et al.* ..... (A) 86
Correlation of oral surface temperatures and the lesions of leprosy. Scheepers, A. ..... (O) 214
Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-Lesion Multicentre Trial Group ..... (A) 82
Epidemiological significance of first skin lesion in leprosy. Abraham, S., *et al.* ..... (O) 131
Giant lesions in histoid leprosy. Ramesh, V., *et al.* ..... (C) 232
[Osteoarticular lesions in leprosy.] Terencio de las Aguas, J. ..... (A) 106
Progression of bone lesions in cured leprosy patients. Carpintero, P., *et al.* ..... (A) 517
[Reactivity of cutaneous leprosy lesions to epicutaneous and intradermal immunologic agents.] dos Santos, I. B. and Pereira, A. C., Jr. ..... (A) 265
Recombinant interleukin-2 in lepromatous leprosy lesions: immunological and microbiological consequences. Villahermosa, L. G., *et al.* ..... (A) 509
Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like *M. leprae* T-cell reactivity in lesional skin—a follow-up study. Verhagen, C. E., *et al.* ..... (A) 272
Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome—a randomized, double-blind, placebo-controlled trial. Hamuryudan, V., *et al.* ..... (A) 295
The primary lesion in leprosy. Porichha, D. and Ramesh, V. ..... (C) 388

Leukocyte(s),
Dapsone hydroxylamine inhibits the LTB4-induced chemotaxis of polymorphonuclear leukocytes into human skin: results of a pilot study. Wozel, G., *et al.* ..... (A) 83
Extravasation of leukocytes assessed by intravital microscopy: effect of thalidomide. Schneider, J., *et al.* ..... (A) 118

Lipid(s),
An acyl-CoA synthase (acoas) gene adjacent to the mycocerosic acid synthase (mas) locus is necessary for mycocerosyl lipid synthesis in *M. tuberculosis* var. *bovis* BCG. Fitzmaurice, A. M. and Kolattukudy, P. E. ..... (A) 414
Characterization of leprosy based on the nasal lipid profile. Srikanth, N. C., *et al.* ..... (A) 99

Down-regulatory effect of *M. leprae* cell wall lipids on phagocytosis, oxidative respiratory burst and tumor cell killing by mouse bone marrow-derived macrophages. Moura, A. C. N., *et al.* ..... (A) 267
Lipids from *M. leprae* cell wall suppress T-cell activation *in vivo* and *in vitro*. Moura, A. C. N. and Mariano, M. ..... (A) 267

Lipoarabinomannan (LAM),
Biosynthesis of mycobacterial lipoarabinomannan. Besra, G. S., *et al.* ..... (A) 95
Characterization of mannose receptor-dependent phagocytosis mediated by *M. tuberculosis* lipoarabinomannan. Kang, B. K. and Schlesinger, L. S. ..... (A) 505
Chemokine secretion by human polymorphonuclear granulocytes after stimulation with *M. tuberculosis* and lipoarabinomannan. Riedel, D. D. and Kaufmann, S. H. E. ..... (A) 91
Expression of monocyte chemotactic protein-3 in human monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. Vouret Craviari, V., *et al.* ..... (A) 272
Involvement of antilipoarabinomannan antibodies in classical complement activation in tuberculosis. Hetland, G., *et al.* ..... (A) 265
Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with profound physiological effects. Chatterjee, D. and Khoo, K. H. ..... (A) 274
[Serological surveillance wih PGL-I and LAM-beta for leprosy relapse.] Wang, D., *et al.* ... (A) 86

Lipoprotein,
A novel 27 kDa lipoprotein antigen from *M. bovis*. Bibi, F., *et al.* ..... (A) 95
A novel mycobacterial antigen relevant to cellular immunity belongs to a family of secreted lipoproteins. Oftung, F., *et al.* ..... (A) 281
Alpha-1-antichymotrypsin is not associated with the increased frequency of apolipoprotein-E-epsilon-4 allele in elderly nondemented leprosy patients. Endoh, M., *et al.* ..... (A) 257

Liver,
A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma. Ruff, P., *et al.* ..... (A) 428
[Pathological findings of the liver in Hansen's disease.] Matsumoto, K., *et al.* ..... (A) 410
Rifampin and rifabutin and their metabolism by human liver esterases. Jamis Dow, C. A., *et al.* (A) 80

Lupus,
Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Stevens, R. J., *et al.* ..... (A) 304

Lymphocyte(s),
A case of lymphocytic vasculitis with infiltration of dermal nerves resembling indeterminate leprosy. Job, C. K., *et al.* ..... (E) 49
Animal model of leprous neuritis; comparison of transfer of CD4 and CD8 lymphocytes into *M. leprae*-inoculated nude mice. Goto, M., *et al.* ..... (A) 432
Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Zea, A. H., *et al.* ..... (A) 272
Effect of thalidomide on apoptosis of lymphocytes and neutrophils. Aseffa, A., *et al.* ..... (A) 87
Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for *M. tuberculosis*. Lalvani, T., *et al.* ..... (A) 297
Induction of *in vitro* human macrophage anti-*M. tuberculosis* activity: requirement for IFN-gamma and primed lymphocytes. Bonecini Almeida, M. G., *et al.* ..... (A) 421
Lymphocyte-dependent inhibition of growth of virulent *M. tuberculosis* H37Rv within human monocytes: requirement for CD4+ T cells in PPD-positive, but not PPD-negative subjects. Silver, R. F., *et al.* ..... (A) 303
Lymphocytes expressing Fc gamma receptors suppress antigen induced proliferation in cells from guinea pigs infected with *M. tuberculosis*. Bartow, R. A. and McMurray, D. N. .... (A) 518
Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. Haslett, P. A. J., *et al.* ..... (A) 505
The T cell receptor subsets of lymphocytes in bronchoalveolar lavage in patients with active pulmonary tuberculosis. Uh, S. T., *et al.* ..... (A) 428

Macrophage(s),
A macrophage invasion mechanism of pathogenic mycobacteria. Schorey, J. S., *et al.* ..... (A) 99
A tumor necrosis factor mimetic peptide activates a murine macrophage cell line to inhibit mycobacterial growth in a nitric oxide-dependent fashion. Britton, W. J., *et al.* ..... (A) 408

ATP-induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z(P2X7) receptors. Lammas, D. A., *et al.* ..... (A) 113
Apoptosis of human monocytes and macrophages by *M. avium* sonicate. Hayashi, T., *et al.* .. (A) 295
Cloning, sequencing and expression of mig gene of *M. avium*, which codes for a secreted macrophage-induced protein. Plum, G., *et al.* ..... (A) 117
Differential induction of apoptosis by virulent *M. tuberculosis* in resistant and susceptible murine macrophages —role of nitric oxide and mycobacterial products. Rojas, M., *et al.* .. (A) 92
Differential potentiation of antimycobacterial activity and reactive nitrogen intermediate-producing ability of murine peritoneal macrophages actived by interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha). Sato, K., *et al.* ..... (A) 410
Down-regulatory effect of *M. leprae* cell wall lipids on phagocytosis, oxidative respiratory burst and tumor cell killing by mouse bone marrow-derived macrophages. Moura, A. C. N., *et al.* ..... (A) 267
Effect of *M. avium* infection on the influx, accumulation, and efflux of KRM-1648 by human macrophages. Bermudez, L. E. and Inderlied, C. B. ..... (A) 80
Fas ligand-induced apoptosis of infected human macrophages reduced the viability of intracellular *M. tuberculosis*. Oddo, M., *et al.* ..... (A) 507
Genetics of host resistance and susceptibility to intramacrophage pathogens: a study of multicase families of tuberculosis, leprosy and leishmaniasis in northeastern Brazil. Blackwell, J. M. ..... (A) 262
Growth of *M. leprae* in macrophages *in vitro*. Osawa, N. ..... (A) 98
Induction of apoptosis in murine macrophages by *M. tuberculosis* is reactive oxygen intermediate-independent. Rojas, M., *et al.* ..... (A) 525
Induction of gamma interferon production in human alveolar macrophages by *M. tuberculosis*. Fenton, M. J., *et al.* ..... (A) 294
Induction of *in vitro* human macrophage anti-*M. tuberculosis* activity: requirement for IFN-gamma and primed lymphocytes. Bonecini Almedia, M. G., *et al.* ..... (A) 421
Inhibition of virulent *M. tuberculosis* by Bcg^r and Bcg^s macrophages correlates with nitric oxide production. Arias, M., *et al.* ..... (A) 261
M. lepraemurium, a well-adapted parasite of macrophages: I. Oxygen metabolites. Rojas-Espinosa, O., *et al.* ..... (O) 365
Mechanisms of nitric oxide production by macrophages that express anti-*M. leprae* response. Fukutomi, Y., *et al.* ..... (A) 432
Schwann cell extracellular matrix protein production in modulated *M. leprae* and macrophage secretory products. Singh, N., *et al.* ..... (A) 100
Synergistic activities of clarithromycin and pyrazinamide against *M. tuberculosis* in human macrophages. Mor, N. and Esfandiari, A. ..... (A) 115
Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin™) stimulates neutrophils and tissue macrophages and induced an effective nonspecific response against *M. avium* in mice. Bermudez, L. E., *et al.* ..... (A) 519

Metabolism,
Comparison of the *in vitro* cytotoxicity of hydroxylamine metabolites of sulfamethoxazole and dapsone. Reilly, T. P., *et al.* ..... (A) 252
Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. Tingle, M. D., *et al.* ..... (A) 253
M. lepraemurium, a well-adapted parasite of macrophages: I. Oxygen metabolites. Rojas-Espinosa, O., *et al.* ..... (O) 365
Rifampin and rifabutin and their metabolism by human liver esterases. Jamis Dow, C. A., *et al.* ..... (A) 80
The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. Haslett, P., *et al.* ..... (A) 111

Mice (murine),
A tumor necrosis factor mimetic peptide activates a murine macrophage cell line to inhibit mycobacterial growth in a nitric oxide-dependent fashion. Britton, W. J., *et al.* ..... (A) 408
Activation of CD8 T cells with specificity for mycobacterial heat shock protein 60 in *M. bovis* bacillus Calmette-Guerin vaccinated mice. Zugel, U. and Kaufmann, S. H. E. ..... (A) 94
Adequate expression of protective immunity in the absence of granuloma formation in *M. tuberculosis*-infected mice with a disruption in the intracellular adhesion molecule 1 gene. Johnson, C. M., *et al.* ..... (A) 425

Anti-tumor immunity induced by murine melanoma cells transduced with the *M. tuberculosis* gene encoding the 38-kDa antigen. Sfondrini, L., *et al.* ..... (A) 302
Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against *M. leprae* in mice and in lepromatous patients. Ji, B., *et al.* ..... (A) 399
Cellular reaction to *M. avium* complex (MAC) clinical isolates differing in hemolytic activity and virulence for C57BL/6 mice. Brzychy, M., *et al.* ..... (A) 421
Collagen profile in sciatic nerves of *M. leprae*-inoculaed mice correlates with *in vitro* collagen production by Schwann cells. Singh, N., *et al.* ..... (C) 238
Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. Tingle, M. D., *et al.* ..... (A) 253
Differential induction of apoptosis by virulent *M. tuberculosis* in resistant and susceptible murine macrophages —role of nitric oxide and mycobacterial products. Rojas, M., *et al.* . (A) 92
Differential potentiation of antimycobacterial activity and reactive nitrogen intermediate-producing ability of murine peritoneal macrophages actived by interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha). Sato, K., *et al.* ..... (A) 410
Down-regulatory effect of *M. leprae* cell wall lipids on phagocytosis, oxidative respiratory burst and tumor cell killing by mouse bone marrow-derived macrophages. Moura, A. C. N., *et al.* ..... (A) 267
Effects of aminoguanidine on latent murine tuberculosis. Flynn, J. L., *et al.* ..... (A) 423
Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Baldwin, S. L., *et al.* ..... (A) 504
Identification and characterization of a 29-kilodalton protein from *M. tuberculosis* culture filtrate recognized by mouse memory effector cells. Rosenkrands, I., *et al.* ..... (A) 511
Identification and characterization of protective T cells in hsp 65 DNA-vaccinated and *M. tuberculosis*-infected mice. Bonato, V. L. D., *et al.* ..... (A) 263
Identification of potential CD8+ T-cell epitopes of the 19 kDa and AhpC proteins from *M. tuberculosis*. No evidence for CD8+ T-cell priming against the identified peptides after DNA-vaccination of mice. Erb, K. J., *et al.* ..... (A) 423
Induction of apoptosis in murine macrophages by *M. tuberculosis* is reactive oxygen intermediate-independent. Rojas, M., *et al.* ..... (A) 525
Infection of mice with *M. bovis*-bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. Erb, K. J., *et al.* ..... (A) 293
Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed *M. vaccae*. Wang, C. C. and Rook, G. A. W. ..... (A) 429
Inhibition of multiplication of *M. leprae* in mouse foot pads by immunization with ribosomal fraction and culture filtrate from *M. bovis* BCG. Matsuoka, M., *et al.* ..... (A) 100
Lethal tuberculosis in interleukin-6-deficient mutant mice. Ladel, C. H., *et al.* ..... (A) 91
M. tuberculosis-driven processes in gene-disrupted mice. Cooper, A. M., *et al.* ..... (A) 109
Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-gamma and IL-4 knockout mice—analysis of local and regional cytokine and chemokine networks. Chensue, S. W., *et al.* ..... (A) 88
Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Hernandez Pando, R., *et al.* ..... (A) 90
Rational basis of interleukin-12 immunotherapy for established mycobacterial infection in mice. Kobayashi, K., *et al.* ..... (A) 434
Resistance ranking of some common inbred mouse strains to *M. tuberculosis* and relationship to major histocompatibility complex haplotype and Nramp1 gene type. Medina, E. and North, R. J. ..... (A) 299
Susceptibility to *M. leprae* of ALY (alymphoplasia) mice and IFN-gamma induction in the culture supernatant of spleen cells. Yogi, Y., *et al.* ..... (O) 464
Thalidomide protects mice against LPS-induced shock. Moreira, A. L., *et al.* ..... (A) 115
Thalidomide reduced MPTP-induced decrease in striatal dopamine levels in mice. Boireau, A., *et al.* ..... (A) 108
Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin™) stimulates neutrophils and tissue macrophages and induced an effective nonspecific response against *M. avium* in mice. Bermudez, L. E., *et al.* ..... (A) 519
Vaccination with recombinant vaccinia viruses protects mice against *M. tuberculosis* infection. Zhu, X., *et al.* ..... (A) 123
Viability determination of *M. leprae*: comparison of normal mouse foot pad and bacillary ATP bioluminescence assay. Gupta, U. D., *et al.* ..... (A) 277

Mice, nude,
Animal model of leprous neuritis; comparison of transfer of CD4 and CD8 lymphocytes into *M. leprae*-inoculated nude mice. Goto, M., *et al.* ..... (A) 432
[Effect of minocycline made in China on vitality of *M. leprae* in nude mice.] Wang, H., *et al.* (A) 418

Microscopy,
Extravasation of leukocytes assessed by intravital microscopy: effect of thalidomide. Schneider, J., *et al.* ..... (A) 118

Minocycline,
Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against *M. leprae* in mice and in lepromatous patients. Ji, B., *et al.* ..... (A) 399
[Effect of minocycline made in China on vitality of *M. leprae* in nude mice.] Wang, H., *et al.* (A) 418

Molecular biology (see also **DNA, Genetics**),
Adequate expression of protective immunity in the absence of granuloma formation in *M. tuberculosis*-infected mice with a disruption in the intracellular adhesion molecule 1 gene. Johnson, C. M., *et al.* ..... (A) 425
Cotton wool swabs provide a convenient medium for the collection, transport and storage of sputum for the subsequent molecular investigation of *M. tuberculosis*. Wiessler, R. E., *et al.* ..... (A) 122
Fractionation of mycobacterial integral membrane proteins by continuous elution SDS-PAGE reveals the immunodominance of low molecular weight subunits for human T cells. Mehrotra, J., *et al.* ..... (A) 97
Molecular basis of clarithromycin activity against *M. avium* and *M. smegmatis*. Doucet Populaire, F., *et al.* ..... (A) 292
Molecular beacon sequence analysis for detecting drug resistance in *M. tuberculosis*. Piatek, A. S., *et al.* ..... (A) 427
Molecular fingerprinting of *M. tuberculosis*: how can it help the clinician? Behr, M. A. and Small, P. M. ..... (A) 108
Molecular mechanism of neural targeting of *M. leprae*: role of the G domain of laminin-2 and its receptor alpha dystroglycan. Rambukkana, A., *et al.* ..... (A) 436
Use of different molecular typing techniques for bacteriological follow up in a clinical trial with AIDS patients with *M. avium* bacteremia. Picardeau, M., *et al.* ..... (A) 116

Monkey(s),
Impaired responses to *M. leprae* antigens in rhesus monkeys experimentally inoculated with simian immunodeficiency virus and *M. leprae*. Gormus, B. J., *et al.* ..... (A) 418
Protective immunization of monkeys with BCG or BCG plus heat killed *M. leprae*: clinical results. Gormus, B. J., *et al.* ..... (A) 417
Spontaneous leprosy in a wild-caught cynomolgus macaque. Valverde, C. R., *et al.* ..... (O) 140
Thalidomide may impede cell migration in primates by downregulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. McCarty, M. F. ..... (A) 114

Monocyte(s),
Activity of new quinolones against intracellular *M. avium* in human monocytes. Venkataprasad, N., *et al.* ..... (A) 305
Apoptosis of human monocytes and macrophages by *M. avium* sonicate. Hayashi, T., *et al.* ... (A) 295
Expression of monocyte chemotactic protein-3 in human monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. Vouret Craviari, V., *et al.* ..... (A) 272
Lymphocyte-dependent inhibition of growth of virulent *M. tuberculosis* H37Rv within human monocytes: requirement for CD4+ T cells in PPD-positive, but not PPD-negative subjects. Silver, R. F., *et al.* ..... (A) 303
M. bovis bacillus Calmette Guerin infection prevents apoptosis of resting human monocytes. Kremer, L., *et al.* ..... (A) 90
Monocytes modulate enhancement of HIV-I replication by *M. tuberculosis*. De Hass, C. J. C., *et al.* ..... (A) 264
Processing of *M. tuberculosis* bacilli by human monocytes for CD4+ alpha beta and gamma delta T cells: role of particulate antigen. Balaji, K. N. and Boom, W. H. ..... (A) 261
Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes. Tentori, L., *et al.* ..... (A) 271

Morbidity,
Epidemiological aspects of ocular morbidity in leprosy affected persons. Sundar Rao, P. S. S., *et al.* ..... (A) 405
Ocular morbidity in a sample of 150 treated leprosy patients. Thompson, K. ..... (A) 405
Psychiatric morbidity in leprosy and psoriasis—a comparative study. Bharath, S., *et al.* .... (A) 255

Multidrug therapy (MDT),
[Bacterial change and relapse after MDT in 157 cases of MB leprosy.] Li, W., *et al.* ..... (A) 400
Borderline tuberculoid leprosy: clinicopathological evaluation of multidrug therapy. Kar, P. K. and Dhaka, R. S. ..... (A) 251
Clinical and histopathological activity in paucibacillary leprosy patients after fixed-duration multidrug therapy. Ebenezer, G. J., *et al.* ..... (A) 89
Delayed resolution versus treatment failure in paucibacillary leprosy patients under six months fixed duration multidrug therapy. Job, C. K., *et al.* ..... (A) 81
[Disability among 1522 cases of leprosy using MDT.] Dan, Z., *et al.* ..... (A) 105
Does MDT arrest transmission of leprosy to household contacts? Vijayakumaran, P., *et al.* .. (O) 125
[Effects of MDT for 13 years in Mengla County, Yunnan.] Ma, J. ..... (A) 103
[Effects of a modified MDT regimen on 122 cases of MB leprosy.] Chen, J., *et al.* ..... (A) 250
Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-Lesion Multicentre Trial Group ..... (A) 82
[Efficiency of MDT in 59 cases of MB leprosy.] Qu, T. ..... (A) 4-1
[FD MDT for patients with MB leprosy.] Li, H., *et al.* ..... (A) 400
[Five-year monitoring for 120 persons who had MB leprosy and used MDT.] Lai, Z., *et al.* .. (A) 81
[Histopathological features five years after MDT in 572 cases of MB leprosy.] Wang, Y., *et al.* (A) 83
Incidence of nerve damage in leprosy patients treated with MDT. Solomon, S., *et al.* ..... (O) 451
Leprosy disabilities: the impact of multidrug therapy (MDT). Ladhani, S. ..... (A) 498
Leprosy elimination campaigns—reaching every patient in every village. World Health Organization. ..... (A) 499
[Leprosy in Guangzhou city before and after MDT.] Ma, Q. ..... (A) 103
MDT and transmission. Hastings, R. C. ..... (E) 224
[MDT plus ofloxacin in MB leprosy.] Zhu, R. ..... (A) 401
[Monitoring for seven years after MDT in 604 cases of MB leprosy.] Zhou, T. ..... (A) 83
[On the course of MDT for MB leprosy.] Zu, Y., *et al.* ..... (A) 84
Patterns of indoor admissions of leprosy patients in a pre-MDT and post-MDT era and a role for leprosy referral hospital in leprosy integration programme. Prabhavalkar, A. B. and Ansari, K. ..... (A) 79
Progress towards leprosy elimination. World Health Organization. ..... (A) 499
[Risk of relapse following FD MDT in leprosy.] Li, H., *et al.* ..... (A) 498
Serum zinc, copper, magnesium, proteins and superoxide dismutase in leprosy patients on multidrug therapy—a follow up study. Sethi, N. C., *et al.* ..... (A) 259
Shortening duration of treatment of multibacillary leprosy. World Health Organization. ..... (A) 500
[Shortening treatment duration of leprosy with MDT plus ofloxacin.] Xue, W., *et al.* ..... (A) 254
[Socio-medical investigation on leprosy following MDT (I); knowledge, attitude and behaviour of leprosy patients to MDT.] Chen, X., *et al.* ..... (A) 79
Ulnar abscess: 4 months after release from control with paucibacillary-multidrug therapy. Darius, E. J., *et al.* ..... (A) 257
Ulner nerve abscess in a multibacillary patient during post multidrug therapy surveillance. Abraham, S., *et al.* ..... (A) 255
Why relapse occurs in PB leprosy patients after adequate MDT despite they are Mitsuda reactive: lessons from Convit's experiment on bacteria-clearing capacity of lepromin-induced granuloma. Chaudhuri, S., *et al.* ..... (O) 182

Myanmar (Burma),
A case-control study of the effectiveness of the BCG vaccine for preventing leprosy in Yangon, Myanmar. Bertolli, J., *et al.* ..... (A) 101
Third Independent Evaluation of the Leprosy Elimination Program, 4–18 November 1997. McDougall, A. C. ..... (N) 76

Mycobacteria (see also individual species),
A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. Tsenova, L., *et al.* ..... (A) 526

A macrophage invasion mechanism of pathogenic mycobacteria. Schorey, J. S., *et al.* ..... (A) 99
A tumor necrosis factor mimetic peptide activates a murine macrophage cell line to inhibit mycobacterial growth in a nitric oxide-dependent fashion. Britton, W. J., *et al.* ..... (A) 408
ATP-induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z(P2X7) receptors. Lammas, D. A., *et al.* ..... (A) 113
Ability of lymphokine-activated killer cells to lyse mycobacteria-infected cells. Chiplunkar, S. V., *et al.* ..... (A) 264
Bacille Calmette-Guerin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. Hoft, D. F., *et al.* ..... (A) 522
Cytokine networks with infection: mycobacterial infections, leishmaniasis, human immunodeficiency virus infection, and sepsis. Dipiro, J. T ..... (A) 265
Cytokines and mycobacterial infections. Tantawichien, T. ..... (A) 508
Differential induction of apoptosis by virulent *M. tuberculosis* in resistant and susceptible murine macrophages—role of nitric oxide and mycobacterial products. Rojas, M., *et al.* .. (A) 92
Distribution of mevalonate and glyceraldehyde 3 phosphate/pyruvate routes for isoprenoid biosynthesis in some gram-negative bacteria and mycobacteria. Putra, S. R., *et al.* ..... (A) 511
Effects of mycobacteria on regulation of apoptosis in mononuclear phagocytes. Klinger, K., *et al.* ..... (A) 266
Expression systems for study of mycobacterial gene regulation and development of recombinant BCG vaccines. DasGupta, S. K., *et al.* ..... (A) 520
Fractionation of mycobacterial integral membrane proteins by continuous elution SDS-PAGE reveals the immunodominance of low molecular weight subunits for human T cells. Mehrotra, J., *et al.* ..... (A) 97
Identification and analysis of "extended-10" promoters from mycobacteria. Bashyam, M. D. and Tyagi, A. K. ..... (A) 413
Identification of novel intergenic repetitive units in a mycobacterial two-component system operon. Supply, P., *et al.* ..... (A) 283
Identification of phosphatidylinositol mannoside as a mycobacterial adhesion mediating both direct and opsonic binding in nonphagocytic mammalian cells. Hoppe, H. C., *et al.* ..... (A) 96
Influence of mycobacterial virulence and culture condition on gamma delta T cell activation. Schoel, B. and Kaufmann, S. H. E. ..... (A) 411
Inhibition of UDP-Gal mutase and mycobacterial galactan biosynthesis by pyrrolidine analogues of galactofuranose. Lee, R. E., *et al.* ..... (A) 97
Interaction of oligodeoxynucleotides with mycobacteria: implications for new therapeutic strategies. Attia, S., *et al.* ..... (A) 509
Intractable mycobacterial infections associated with genetic defects in the receptor for interferon gamma: what does this tell us about immunity to mycobacteria? Rook, G. A. W. .... (A) 93
Mammalian heterotrimeric G-protein-like proteins in mycobacteria: implications for cell signalling and survival in eukaryotic host cells. Shankar, S., *et al.* ..... (A) 282
Modulation of protective and pathological immunity in mycobacterial infections. Ottenhoff, T. H. M., *et al.* ..... (A) 91
Mycobacteria in boreal coniferous forest soils. Iivanainen, E. K., *et al.* ..... (A) 113
Mycobacterial Diseases Part I: Clinical Frontiers, A. Malin and K. P. W. J. McAdam, eds. .. (A) 496
Mycobacterial linear plasmids have an invertron-like structure related to other linear replicons in actinomycetes. Picardeau, M. and Vincent, V. ..... (A) 524
Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homology. Cunningham, A. F. and Spreadbury, C. L. ..... (A) 275
Organization and copy number initiator tRNA genes in slow- and fast-growing mycobacteria. Vasanthakrishna, M., *et al.* ..... (A) 512
Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Hernandez Pando, R., *et al.* ..... (A) 90
Rational basis of interleukin-12 immunotherapy for established mycobacterial infection in mice. Kobayashi, K., *et al.* ..... (A) 434
Role of embB in natural and acquired resistance to ethambutol in mycobacteria. Alcaide, F., *et al.* ..... (A) 94
SOS induction in mycobacteria: analysis of the DNA-binding activity of a LexA-like repressor and its role in DNA damage induction of the recA gene from *M. smegmatis.* Durbach, S. I., *et al.* ..... (A) 95
Severe mycobacterial and *Salmonella* infections in interleukin 12 receptor-deficient patients. de Jong, R., *et al.* ..... (A) 408

Specific serological diagnosis of leprosy with a recombinant *M. leprae* protein purified from a rapidly growing mycobacterial host. Triccas, J. A., *et al.* . . . . . (A) 509
Stabilized, freeze-dried PCR mix for detection of mycobacteria. Klatser, P. R., *et al.* . . . . . (A) 415
Strategies used by pathogenic and nonpathogenic mycobacteria to synthesize rRNA. Gonzalez y Merchand, J. A., *et al.* . . . . . (A) 276
Suppression of the growth of six potentially pathogenic mycobacteria by beta-lactam/beta-lactamase inhibitors. Prabhakaran, K., *et al.* . . . . . (A) 252
Sweet's syndrome associated with nontuberculous mycobacterial infection: a report of five cases. Choonhakaran, C., *et al.* . . . . . (A) 519
Synthesis of beta-D-arabinofuranosyl-1-monophosphoryl polyprenols: examination of their function as mycobacterial arabinosyl transferase donors. Lee, R. E., *et al.* . . . . . (A) 415
Synthetic arabinofuranosyl oligosaccharides as mycobacterial arabinosyl transferase substrates. Ayers, J. D., *et al.* . . . . . (A) 249
The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Alangaden, G. J. and Lerner, S. A. . . . . (A) 248
The novel fibronectin-binding motif and key residues of mycobacteria. Naito, M., *et al.* . . . . (A) 280
Understanding the phenomenon of persistence in mycobacterial infections. Gupta, U. D. and Katoch, V. M. . . . . (A) 277

Mycobacterium aurum,
Accumulation of norfloxacin by *M. aurum* and *M. smegmatis*. Williams, K. J., *et al.* . . . . . (A) 283

Mycobacterium avium,
Activity of new quinolones against intracellular *M. avium* in human monocytes. Venkataprasad, N., *et al.* . . . . . (A) 305
Apoptosis of human monocytes and macrophages by *M. avium* sonicate. Hayashi, T., *et al.* . . (A) 295
Cloning, sequencing and expression of mig gene of *M. avium*, which codes for a secreted macrophage-induced protein. Plum, G., *et al.* . . . . . (A) 117
Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to *M. avium*. May, T., *et al.* . . . . (A) 114
Determination of a 15437 bp nucleotide sequence around the inhA gene of *M. avium* and similarity analysis of the products of putative ORFs. Labo, M., *et al.* . . . . . (A) 296
Effect of *M. avium* infection on the influx, accumulation, and efflux of KRM-1648 by human macrophages. Bermudez, L. E. and Inderlied, C. B. . . . . (A) 80
Emergence of *M. avium* populations resistant to macrolides during experimental chemotherapy. Bermudez, L. E., *et al.* . . . . . (A) 290
Identification and cloning of the *M. avium* folA gene, required for dihydrofolate reductase activity. Ginkel, S. Z., *et al.* . . . . . (A) 276
Interaction of *M. avium* with environmental amoebae enhances virulence. Cirillo, J. D., *et al.* (A) 109
Mechanisms involved in the intrinsic isoniazid resistance of *M. avium*. Mdluli, K., *et al.* . . . . (A) 415
Molecular basis of clarithromycin activity against *M. avium* and *M. smegmatis*. Doucet Populaire, F., *et al.* . . . . . (A) 292
Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against *M. avium*. Horgen, L., *et al.* . . . . . (A) 251
T-cell-independent granuloma formation in response to *M. avium*: role of tumour necrosis factor-alpha and interferon gamma. Smith, D., *et al.* . . . . . (A) 270
The pncA gene from naturally pyrazinamide-resistant *M. avium* encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant *M. tuberculosis* complex organisms. Sun, Z., *et al.* . . . . . (A) 100
Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin™) stimulates neutrophils and tissue macrophages and induced an effective nonspecific response against *M. avium* in mice. Bermudez, L. E., *et al.* . . . . . (A) 519
Use of different molecular typing techniques for bacteriological follow up in a clinical trial with AIDS patients with *M. avium* bacteremia. Picardeau, M., *et al.* . . . . . (A) 116

***Mycobacterium avium* complex,**
Cellular reaction to *M. avium* complex (MAC) clinical isolates differing in hemolytic activity and virulence for C57BL/6 mice. Brzychy, M., *et al.* . . . . . (A) 421
Comparison of CO_2 generation (BACTEC) and viable-count methods to determine the postantibiotic effect of antimycobacterial agents against *M. avium* complex. Zhanel, G. G., *et al.* . . (A) 306
Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin and ethambutal for *M. avium* complex bacteremia: a multivariate analysis. Shafran, S. D., *et al.* . . . . . (A) 302

Mycobacterium bovis (see also **BCG**),
A novel 27 kDa lipoprotein antigen from *M. bovis*. Bibi, F., *et al.* ..... (A) 95
Activation of CD8 T cells with specificity for mycobacterial heat shock protein 60 in *M. bovis* bacillus Calmette-Guerin vaccinated mice. Zugel, U. and Kaufmann, S. H. E. ..... (A) 94
Infection of mice with *M. bovis*-bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. Erb, K. J., *et al.* ..... (A) 293
Inhibition of multiplication of *M. leprae* in mouse foot pads by immunization with ribosomal fraction and culture filtrate from *M. bovis* BCG. Matsuoka, M., *et al.* ..... (A) 100
M. bovis bacille Calmete-Guerin strains secreting listeriolysin of *Listeria monocytogenes*. Hess, J., *et al.* ..... (A) 409
M. bovis bacillus Calmette Guerin infection prevents apoptosis of resting human monocytes. Kremer, L., *et al.* ..... (A) 90
Mycobacteriophage L5 infection of *M. bovis* BCG: implications for phage genetics in the slow-growing mycobacteria. Fullner, K. J. and Hatfull, G. F. ..... (A) 96
"Proteomic contigs" of *M. tuberculosis* and *M. bovis* (BCG) using novel immobilised pH gradients. Urguhart, B. L., *et al.* ..... (A) 120
Recognition of a common mycobacterial T-cell epitope in MPB59 of *M. bovis*. Lightbody, K. A., *et al.* ..... (A) 426
Two-dimensional electrophoretic analysis of humoral responses to culture filtrate of *M. bovis* BCG in patients with leprosy and tuberculosis. Naito, M., *et al.* ..... (O) 208

Mycobacterium cheloni (chelonae),
The antimicrobial susceptibility of *M. chelonae* isolated from corneal ulcer. Hu, F. R., *et al.* .. (A) 112

Mycobacterium genavense,
Inhibitory effects of polyoxyethylene stearate, PANTA, and neutral pH on growth of *M. genavense* in BACTEC primary cultures. Realini, L., *et al.* ..... (A) 117
Standardized BACTEC method to measure clarithromycin susceptibility of *M. genavense*. Carlson, L. D. C., *et al.* ..... (A) 291

Mycobacterium gordonae,
Cloning of the antigen 85A from *M. gordonae* and its use for the specific PCR identification of these mycobacteria. Dumonceaux, M., *et al.* ..... (A) 110

Mycobacterium intracellulare,
Site-directed mutagenesis and virulence assessment of the katG gene of *M. intracellulare*. Marklund, B.-I., *et al.* ..... (A) 523

Mycobacterium kansasii,
AIDS-related *M. kansasii* infection with initial resistance to clarithromycin. Burman, W. J., *et al.* (A) 510

Mycobacterium leprae,
[A PCR for 26s rRNA of *M. leprae*.] Hou, W., *et al.* ..... (A) 97
A simple dipstick assay for the detection of antibodies to phenolic glycolipid I of *M. leprae*. Buhrer, S. S., *et al.* ..... (A) 263
Adherence of *M. leprae* to the nasal mucosa is influenced by surface integrity and viability. Sethna, B. K., *et al.* ..... (A) 269
An epidemiological study of *M. leprae* infection and prevalence of leprosy in an endemic district of North Maluku, Indonesia. Izumi, S., *et al.* ..... (A) 433
Animal model of leprous neuritis; comparison of transfer of CD4 and CD8 lymphocytes into *M. leprae*-inoculated nude mice. Goto, M., *et al.* ..... (A) 432
Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against *M. leprae* in mice and in lepromatous patients. Ji, B., *et al.* ..... (A) 399
Bilateral iridocyclitis caused by *M. leprae* diagnosed through paracentesis. Campos, W. R., *et al.* ..... (A) 402
Cellular immune responses of healthy and *M. leprae*-inoculated armadillos (*Dasypus novemcinctus*). Rivero-Nava, L., *et al.* ..... (C) 485
Choosing the decolourizer and its strength to stain *M. leprae*: does it really matter? de Soldenhoff, R., *et al.* ..... (A) 510
Collagen profile in sciatic nerves of *M. leprae*-inoculated mice correlates with *in vitro* collagen production by Schwann cells. Singh, N., *et al.* ..... (C) 238
Comparative *in vitro* activities of rifamycin analogues against *M. leprae*. Dhople, A. M. .... (A) 275
[Detection of *M. leprae* and PGL-I antigen in nasal secretion and skin tissue.] Weng, X., *et al.* (A) 512

Determinant capture by MHC class II DR3 during processing of *M. leprae* 65 kDa heat shock protein by human B cells. Young, S. P., *et al.* ..... (A) 412
Down-regulatory effect of *M. leprae* cell wall lipids on phagocytosis, oxidative respiratory burst and tumor cell killing by mouse bone marrow-derived macrophages. Moura, A. C. N., *et al.* ..... (A) 267
Dual multimodular class A penicillin-binding proteins in *M. leprae*. Lepage S., *et al.* ..... (A) 97
[Effect of MINO on vitality of *M. leprae* in the body of MB leprosy patients.] Shen, J., *et al.* (A) 499
[Effect of minocycline made in China on vitality of *M. leprae* in nude mice.] Wang, H., *et al.* (A) 418
Effect of trifluoperazine on *in vitro* ATP synthesis by *M. leprae*. Katoch, V. M., *et al.* ..... (A) 278
Effects of *M. leprae* infection on gene expression in cultured Schwann cells. Hagge, D., *et al.* (A) 432
[Establishment of high-potent genome DNA library of *M. leprae* and its evaluation.] Yin, Y., *et al.* ..... (A) 513
Growth of *M. leprae* in macrophages *in vitro*. Osawa, N. ..... (A) 98
Growth of *M. leprae in vitro*. Osawa, N. ..... (A) 98
Identification of mycobacterial HSP70 reactive human T cell clones discriminating between *M. tuberculosis* and *M. leprae*. Oftung, F. and Lundin, K. E. A. ..... (A) 280
Immunological characterization of five recombinant *M. leprae* proteins produced in *Escherichia coli*. Suzuki, Y., *et al.* ..... (A) 437
Impaired responses to *M. leprae* antigens in rhesus monkeys experimentally inoculated with simian immunodeficiency virus and *M. leprae*. Gormus, B. J., *et al.* ..... (A) 418
Inhibition of multiplication of *M. leprae* in mouse foot pads by immunization with ribosomal fraction and culture filtrate from *M. bovis* BCG. Matsuoka, M., *et al.* ..... (A) 100
Lipids from *M. leprae* cell wall suppress T-cell activation *in vivo* and *in vitro*. Moura, A. C. N. and Mariano, M. ..... (A) 267
M. leprae binds to a 25-kDa phosphorylated glycoprotein of human peripheral nerve. Suneetha, L. M., *et al.* ..... (A) 412
Mechanisms of nitric oxide production by macrophages that express anti-*M. leprae* response. Fukutomi, Y., *et al.* ..... (A) 432
Molecular mechanism of neural targeting of *M. leprae*: role of the G domain of laminin-2 and its receptor alpha dystroglycan. Rambukkana, A., *et al.* ..... (A) 436
Multidrug-resistance to dapsone, rifampicin, and ofloxacin in *M. leprae*. Cambau, E., *et al.* .. (A) 249
Multiplex sequencing of 1.5 Mb of the *M. leprae* genome. Smith, D. R., *et al.* ..... (A) 99
Neural targeting of *M. leprae* mediated by the G domain of the laminin-alpha 2 chain. Rambukkana, A., *et al.* ..... (A) 268
Polymerase chain reaction assay for the detection and identification of *M. leprae* in patients in the United States. Scollard, D. M., *et al.* ..... (A) 411
Predominant recognition of species-specific determinants of the GroES homologues from *M. leprae* and *M. tuberculosis*. Chua Intra, B., *et al.* ..... (A) 274
Presence of *M. leprae* in the conjunctiva, vitreous body and retina of a patient having lepromatous leprosy. Orefice, F., *et al.* ..... (A) 404
Protective immunization of monkeys with BCG or BCG plus heat killed *M. leprae*: clinical results. Gormus, B. J., *et al.* ..... (A) 417
Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like *M. leprae* T-cell reactivity in lesional skin—a follow-up study. Verhagen, C. E., *et al.* ..... (A) 272
Reverse transcription-PCR detection of *M. leprae* in clinical specimens. Kurabachew, M., *et al.* ..... (A) 415
Schwann cell extracellular matrix protein production in modulated *M. leprae* and macrophage secretory products. Singh, N., *et al.* ..... (A) 100
Sequence data analysis reveals a relationship between LSR2, the recombinant fusion protein mimicking *M. leprae*, and VIF of bovine immunodeficiency virus (BIV). Ramakrishnan, S., *et al.* ..... (A) 281
Serologic assays using the 18-kDa antigen of *M. leprae* expressed in the yeast *Saccaromyces cerevisiae*. Pinho, J. R. R., *et al.* ..... (C) 235
[Serological activity of recombinant alpha-antigen of *M. leprae*.] Yin, Y., *et al.* ..... (A) 94
Specific serological diagnosis of leprosy with a recombinant *M. leprae* protein purified from a rapidly growing mycobacterial host. Triccas, J. A., *et al.* ..... (A) 509
Susceptibility to *M. leprae* of ALY (alymphoplasia) mice and IFN-gamma induction in the culture supernatant of spleen cells. Yogi, Y., *et al.* ..... (O) 464
T-cell responses to major membrane protein II (MMP II) derived from *M. leprae* in leprosy patients. Ohyama, H., *et al.* ..... (A) 435
The activity of rifabutin against *M. leprae* in armadillos. Dhople, A. M. and Williams, S. L. .. (A) 284

Type 1- and type 2-like skin-derived *M. leprae*-responsive T cell clones are characterized by coexpression of IFN-gamma/TNF-alpha and IL-4/IL-5/IL-13, respectively. Verhagen, C. E., *et al.* ..... (A) 271
Viability determination of *M. leprae*: comparison of normal mouse foot pad and bacillary ATP bioluminescence assay. Gupta, U. D., *et al.* ..... (A) 277
Viability of *M. leprae* while undergoing laboratory procedures. Sreevatsa and Katoch, K. ... (A) 283

Mycobacterium lepraemurium,
M. lepraemurium, a well-adapted parasit of macrophages: I. Oxygen metabolites. Rojas-Espinosa, O., *et al.* ..... (O) 365

Mycobacterium paratuberculosis,
[The multiplex polymerase chain reaction assay for the detection of *M. paratuberculosis* DNA in Crohn's disease tissue.] Al Shamali, M., *et al.* ..... (A) 107

Mycobacterium smegmatis,
A single point mutation in the embB gene is responsible for resistance to ethambutol in *M. smegmatis*. Lety, M. A., *et al.* ..... (A) 279
Accumulation of norfloxacin by *M. aurum* and *M. smegmatis*. Williams, K. J., *et al.* ..... (A) 283
Characterization of a beta-lactamase from *M. smegmatis* SN2. Basu, D., *et al.* ..... (A) 413
Characterization of a porin from *M. smegmatis*. Mukhopadhyay, S., *et al.* ..... (A) 97
Characterization of the dnaG locus in *M. smegmatis* reveals linkage of DNA replication and cell division. Klann, A. G., *et al.* ..... (A) 278
Exochelin genes in *M. smegmatis*: identification of an ABC transporter and two non-ribosomal peptide synthetase genes. Zhu, W., *et al.* ..... (A) 513
Expression and efficient export of enzymatically active *M. tuberculosis* glutamine synthetase in *M. smegmatis* and evidence that the information for export is contained within the protein. Harth, G. and Horwitz, M. A. ..... (A) 111
Identification of genetic loci implicated in the survival of *M. smegmatis* in human mononuclear phagocytes. Lagier, B., *et al.* ..... (A) 511
Molecular basis of clarithromycin activity against *M. avium* and *M. smegmatis*. Doucet Populaire, F., *et al.* ..... (A) 292
NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in *M. smegmatis*. Miesel, L., *et al.* ..... (A) 426
Overexpression of the D-ananine racemase gene confers resistance to D-cycloserine in *M. smegmatis*. Caceres, N. E., *et al.* ..... (A) 108
Oxygen depletion induced dormancy in *M. smegmatis*. Dick, T., *et al.* ..... (A) 510
Ribosylative inactivation of rifampin by *M. smegmatis* is a principal contributor to its low susceptibility to this antibiotic. Quan, S., *et al.* ..... (A) 98
sigA is an essential gene in *M. smegmatis*. Gomez, M., *et al.* ..... (A) 510
SOS induction in mycobacteria: analysis of the DNA-binding activity of a LexA-like repressor and its role in DNA damage induction of the recA gene from *M. smegmatis*. Durbach, S. I., *et al.* ..... (A) 95

Mycobacterium tuberculosis,
A novel antioxidant gene from *M. tuberculosis*. Ehert, S., *et al.* ..... (A) 276
A novel pathogenic taxon of the *M. tuberculosis* complex, Canetti: characterization of an exceptional isolate from Africa. Van Soolingen, D., *et al.* ..... (A) 121
A rapid drug susceptibility test for *M. tuberculosis* using the hybridization protection assay. Koga, H., *et al.* ..... (A) 113
Adequate expression of protective immunity in the absence of granuloma formation in *M. tuberculosis*-infected mice with a disruption in the intracellular adhesion molecule 1 gene. Johnson, C. M., *et al.* ..... (A) 425
An acyl-CoA synthase (acoas) gene adjacent to the mycocerosic acid synthase (mas) locus is necessary for mycocerosyl lipid synthesis in *M. tuberculosis* var. *bovis* BCG. Fitzmaurice, A. M. and Kolattukudy, P. E. ..... (A) 414
Anti-tumor immunity induced by murine melanoma cells transduced with the *M. tuberculosis* gene encoding the 38-kDa antigen. Sfondrini, L., *et al.* ..... (A) 302
Characterization of a haemolysin from *M. tuberculosis* with homology to a virulence factor of *Serpulina hyodysenteriae*. Wren, B. W., *et al.* ..... (A) 417
Characterization of human CD8+ T cells reactive with *M. tuberculosis*-infected antigen-presenting cells. Lewisohn, D. M., *et al.* ..... (A) 506

Characterization of mannose receptor-dependent phagocytosis mediated by *M. tuberculosis* lipoarabinomannan. Kang, B. K. and Schlesinger, L. S. ..... (A) 505
Characterization of rpoB mutations in rifampin-resistant clinical *M. tuberculosis* isolates from Greece. Matsiota Bernard, P., *et al.* ..... (A) 298
Chemokine secretion by human polymorphonuclear granulocytes after stimulation with *M. tuberculosis* and lipoarabinomannan. Riedel, D. D. and Kaufmann, S. H. E. ..... (A) 91
Clinical application of the *M. tuberculosis* direct test: case report, literature review, and proposed clinical algorithm. Gladwin, M. T., *et al.* ..... (A) 521
Cloning and expression of an acyl-CoA dehydrogenase from *M. tuberculosis*. Mahadevan, U. and Padmanaban, G. ..... (A) 415
Conditionally replicating luciferase reporter phages: improved sensitivity for rapid detection and assessment of drug susceptibility of *M. tuberculosis*. Carriere, C., *et al.* ..... (A) 274
Conditionally replicating mycobacteriophages: a system for transposon delivery to *M. tuberculosis*. Bardarov, S., *et al.* ..... (A) 107
Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant *M. tuberculosis* clinical isolates. Segura, C., *et al.* ..... (A) 525
Contribution of rpoB mutations to development of rifamycin crossresistance in *M. tuberculosis*. Williams, D. L., *et al.* ..... (A) 416
Cotton wool swabs provide a convenient medium for the collection, transport and storage of sputum for the subsequent molecular investigation of *M. tuberculosis*. Wiessler, R. E., *et al.* ..... (A) 122
Deciphering the biology of *M. tuberculosis* from the complete genome sequence. Cole, S. T., *et al.* ..... (A) 520
Detection of *M. tuberculosis* by PCR analysis of urine and other clinical samples from AIDS and non-HIV-infected patients. Sechi, L. A., *et al.* ..... (A) 119
Differential immunogenicity of novel *M. tuberculosis* antigens derived from live and dead bacilli. Amara, R. R. and Satchidanandam, V. ..... (A) 107
Differential induction of apoptosis by virulent *M. tuberculosis* in resistant and susceptible murine macrophages —role of nitric oxide and mycobacterial products. Rojas, M., *et al.* .. (A) 92
Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant *M. tuberculosis*. Gadre, D. V., *et al.* ..... (A) 497
Efficient allelic exchange and transposon mutagenesis in *M. tuberculosis*. Pelicic, V., *et al.* .. (A) 116
Engineering a change in metal-ion specificity of the iron dependent superoxide dismutase from *M. tuberculosis* X-ray structure analysis of site-directed mutants. Bunting, K., *et al.* . (A) 273
Evaluation of a commercial probe assay for detection of rifampin resistance in *M. tuberculosis* directly from respiratory and nonrespiratory clinical samples. Gamboa, F., *et al.* ..... (A) 521
Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of *M. tuberculosis* complex and its resistance to rifampin. Rossau, R., *et al.* . (A) 118
Expression and efficient export of enzymatically active *M. tuberculosis* glutamine synthetase in *M. smegmatis* and evidence that the information for export is contained within the protein. Harth, G. and Horwitz, M. A. ..... (A) 111
Expression of a gene for a porin-like protein OmpA family from *M. tuberculosis* H37Rv. Senaratne, R. H., *et al.* ..... (A) 525
Extracellular enzyme activities potentially involved in the pathogenicity of *M. tuberculosis*. Raynaud, C., *et al.* ..... (A) 281
Fas ligand-induced apoptosis of infected human macrophages reduced the viability of intracellular *M. tuberculosis*. Oddo, M., *et al.* ..... (A) 507
Flow cytometric testing of susceptibilities of *M. tuberculosis* isolates to ethambutol, isoniazid, and rifampin in 24 hours. Kirk, S. M., *et al.* ..... (A) 425
Gamma delta+ and CD4+ alpha beta+ human T cell subset responses upon stimulation with various *M. tuberculosis* soluble extracts. Batoni, G., *et al.* ..... (A) 407
Genetic advances for studying *M. tuberculosis* pathogenicity. Pelicic, V., *et al.* ..... (A) 416
Genetic diversity in the *M. tuberculosis* complex based on variable numbers of tandem DNA repeats. Frothingham, R. and Meeker-O'Connell, W. A. ..... (A) 424
Green fluorescent protein reporter microplate assay for high throughput screening of compounds against *M. tuberculosis*. Collins, L. A., *et al.* ..... (A) 291
Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for *M. tuberculosis*. Lalvani, T., *et al.* ..... (A) 297
Identification and characterization of a 29-kilodalton protein from *M. tuberculosis* culture filtrate recognized by mouse memory effector cells. Rosenkrands, I., *et al.* ..... (A) 511

Identification and characterization of protective T cells in hsp 65 DNA-vaccinated and *M. tuberculosis*-infected mice. Bonato, V. L. D., *et al.* ..... (A) 263
Identification of iron-regulated proteins of *M. tuberculosis* and cloning of tandem genes encoding a low iron-induced protein and a metal transporting ATPase with similarities to two-component metal transport systems. Calder, K. M. and Horwitz, M. A. ..... (A) 421
Identification of mycobacterial HSP70 reactive human T cell clones discriminating between *M. tuberculosis* and *M. leprae*. Oftung, F. and Lundin, K. E. A. ..... (A) 280
Identification of potential CD8+ T-cell epitopes of the 19 kDa and AhpC proteins from *M. tuberculosis*. No evidence for CD8+ T-cell priming against the identified peptides after DNA-vaccination of mice. Erb, K. J., *et al.* ..... (A) 423
In vitro activity of fluorinated quinolones and macrolides against drug-resistant *M. tuberculosis*. Hoffner, S. E., *et al.* ..... (A) 296
Induction of apoptosis in murine macrophages by *M. tuberculosis* is reactive oxygen intermediate-independent. Rojas, M., *et al.* ..... (A) 525
Induction of gamma interferon production in human alveolar macrophages by *M. tuberculosis*. Fenton, M. J., *et al.* ..... (A) 294
Induction of *in vitro* human macrophage anti-*M. tuberculosis* activity: requirement for IFN-gamma and primed lymphocytes. Bonecini Almedia, M. G., *et al.* ..... (A) 421
Inhibition of virulent *M. tuberculosis* by Bcg^r and Bcg^s macrophages correlates with nitric oxide production. Arias, M., *et al.* ..... (A) 261
Lymphocyte-dependent inhibition of growth of virulent *M. tuberculosis* H37Rv within human monocytes: requirement for CD4+ T cells in PPD-positive, but not PPD-negative subjects. Silver, R. F., *et al.* ..... (A) 303
Lymphocytes expressing Fc gamma receptors suppress antigen induced proliferation in cells from guinea pigs infected with *M. tuberculosis*. Bartow, R. A. and McMurray, D. N. .... (A) 518
M. tuberculosis exploits the CD95/CD95 ligand system of gamma delta T cells to cause apoptosis. Manfredi, A. A., *et al.* ..... (A) 523
M. tuberculosis infection in a green-winged macaw (*Ara chloroptera*): report with public health implications. Washko, R. M., *et al.* ..... (A) 305
M. tuberculosis-driven processes in gene-disrupted mice. Cooper, A. M., *et al.* ..... (A) 109
MTC28, a novel 28-kilodalton proline-rich secreted antigen specific for the *M. tuberculosis* complex. Manca, C., *et al.* ..... (A) 279
Minimal inhibitory concentrations of sulbactam/ampicillin against drug sensitive and drug resistant isolates of *M. tuberculosis*. Paramasivan, C. N., *et al.* ..... (A) 116
Molecular beacon sequence analysis for detecting drug resistance in *M. tuberculosis*. Piatek, A. S., *et al.* ..... (A) 427
Molecular fingerprinting of *M. tuberculosis*: how can it help the clinician? Behr, M. A. and Small, P. M. ..... (A) 108
Monocytes modulate enhancement of HIV-I replication by *M. tuberculosis*. De Hass, C. J. C., *et al.* ..... (A) 264
Nonopsonic binding of *M. tuberculosis* to complement receptor type 3 is mediated by capsular polysaccharides and is strain dependent. Cywes, C., *et al.* ..... (A) 109
Predominant recognition of species-specific determinants of the GroES homologues from *M. leprae* and *M. tuberculosis*. Chua Intra, B., *et al.* ..... (A) 274
Processing of *M. tuberculosis* bacilli by human monocytes for CD4+ alpha beta and gamma delta T cells: role of particulate antigen. Balaji, K. N. and Boom, W. H. ..... (A) 261
Protein synthesis is shut down in dormant *M. tuberculosis* and is reversed by oxygen or heat shock. Hu, Y. M., *et al.* ..... (A) 277
"Proteomic contigs" of *M. tuberculosis* and *M. bovis* (BCG) using novel immobilised pH gradients. Urguhart, B. L., *et al.* ..... (A) 120
Recombinant expression and characterization of the major beta lactamase of *M. tuberculosis*. Voldari, R. K. R., *et al.* ..... (A) 526
Requirement for different presenting cells and for different processing mechanisms by human CD4 T helper clones specific for *M. tuberculosis* antigens. Manca, F., *et al.* ..... (A) 410
Resistance ranking of some common inbred mouse strains to *M. tuberculosis* and relationship to major histocompatibility complex haplotype and Nramp1 gene type. Medina, E. and North, R. J. ..... (A) 299
Restricted structural gene polymorphism in the *M. tuberculosis* complex indicates evolutionarily recent global dissemination. Sreevatsan, S., *et al.* ..... (A) 120
Synergistic activities of antituberculous drugs with cerulenin and trans-cinnamic acid against *M. tuberculosis*. Rastogi, N., *et al.* ..... (A) 524

Synergistic activities of clarithromycin and pyrazinamide against *M. tuberculosis* in human macrophages. Mor, N. and Esfandiari, A. ..... (A) 115
The MTCY428.08 gene of *M. tuberculosis* codes for NAD+ synthetase. Cantoni, R., *et al.* .. (A) 519
The *in vitro* induction of human immunodeficiency virus (HIV) replication in PPD-positive HIV-infected persons by recall antigen response to *M. tuberculosis* is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. Goletti, D., *et al.* ..... (A) 424
The pncA gene from naturally pyrazinamide-resistant *M. avium* encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant *M. tuberculosis* complex organisms. Sun, Z., *et al.* ..... (A) 100
Use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide for rapid detection of rifampin-resistant *M. tuberculosis*. Mshana, R. N., *et al.* ..... (A) 426
Use of a *M. tuberculosis* H37Rv bacterial artifical chromosome library for genome mapping, sequencing, and comparative genomics. Brosch, R., *et al.* ..... (A) 413
Vaccination with plasmid DNA encoding mycobacterial antigen 85 stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by *M. tuberculosis* H37Rv infection. Denis, O., *et al.* ..... (A) 422
Vaccination with recombinant vaccinia viruses protects mice against *M. tuberculosis* infection. Zhu, X., *et al.* ..... (A) 123

***Mycobacterium* ulcerans,**
A large localized outbreak of *M. ulcerans* infection on a temperate southern Australian island. Veitch, M. G. K., *et al.* ..... (A) 304
Detection of *M. ulcerans* in environmental samples during an outbreak of ulcerative disease. Ross, B. C., *et al.* ..... (A) 118
Immunomagnetic separation and PCR for detection of *M. ulcerans*. Robert, B. and Hirst, R. .. (A) 118
In vitro susceptibility of *M. ulcerans* in clarithromycin. Portaels, F., *et al.* ..... (A) 524

Mycobacterium vaccae,
Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed *M. vaccae*. Wang, C. C. and Rook, G. A. W. ..... (A) 429

Mycobacterium w,
Leprosy vaccine: influence of dissolved oxygen levels on growth of a candidate strain (*Mycobacterium w*), and storage stability of the vaccine. Mukhopadhyay, A., *et al.* ..... (A) 506

Nepal,
1998 Dr. Minoo Mehta International Prize awarded to Yog Raj Paudel of Nepal ..... (N) 493
Ocular impairments in an impairment survey of leprosy-affected persons in Nepal. Knuuttila, J. P., *et al.* ..... (A) 404

Nephritis,
Crescentic glomerulonephritis due to rifampin treatment in a patient with pulmonary atypical mycobacteriosis. Ogata, H., *et al.* ..... (A) 252

Nerve(s),
A case of lymphocytic vasculitis with infiltration of dermal nerves resembling indeterminate leprosy. Job, C. K., *et al.* ..... (E) 49
Arsenic poisoning mimicking polyneuritic leprosy. Sharma, V., *et al.* ..... (C) 229
Collagen profile in sciatic nerves of *M. leprae*-inoculated mice correlates with *in vitro* collagen production by Schwann cells. Singh, N., *et al.* ..... (C) 238
[Damage of tibial nerve in 734 leprosy patients.] Zhang, L., *et al.* ..... (A) 290
[Effect of prednisone on silent neuritis in leprosy.] Zhou, L., *et al.* ..... (A) 407
Evaluation of results of surgical decompression of median nerve in leprosy in relation to sensory-motor functions. Husain, S., *et al.* ..... (A) 287
Field treatment of acute nerve function impairment in leprosy using a standardized corticosteroid regimen—first year's experience with 100 patients. Croft, R. P., *et al.* ..... (A) 256
Incidence of nerve damage in leprosy patients treated with MDT. Solomon, S., *et al.* ..... (O) 451
M. leprae binds to a 25-kDa phosphorylated glycoprotein of human peripheral nerve. Suneetha, L. M., *et al.* ..... (A) 412
Molecular mechanism of neural targeting of *M. leprae*: role of the G domain of laminin-2 and its receptor alpha dystroglycan. Rambukkana, A., *et al.* ..... (A) 436

Neural targeting of *M. leprae* medited by the G domain of the laminin-alpha 2 chain. Rambukkana, A., *et al.* ..... (A) 268
Peripheral autonomic nerve dysfunction in asymptomatic leprosy contacts. Wilder-Smith, E., *et al.* ..... (A) 260
Peripheral nerve abscess in leprosy: report of twenty cases. Kumar, P., *et al.* ..... (A) 85
Protective sensibility—its monofilament nylon threshold equivalents in leprosy patients. Malaviya, G. N., *et al.* ..... (A) 86
Results of surgical decompression of ulnar nerve in leprosy. Husain, S., *et al.* ..... (A) 517
Reversal reaction, nerve damage and steroid therapy in three multibacillary HIV positive patients. Arunthathi, S., *et al.* ..... (A) 500
Study on the detection of leprosy reactions and the effect of prednisone on various nerves. Bernink, E. H. M. and Voskens, J. E. J. ..... (A) 84
The Peripheral Nerve in Leprosy and Other Neuropathies by N. H. Antia and V. R. Shetty. Hastings, R. C. ..... (B) 394
The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Sommer, C., *et al.* ..... (A) 303
The occurrence of reactions and impairments in leprosy: experience of the leprosy control program of three provinces in northeastern Thailand, 1987–1995. III. Neural and other impairments. Schreuder, P. A. M. ..... (O) 170
Two objective "archivable" tests for voluntary muscle testing in ulnar and median nerve paralysis. Bourrel, P. ..... (A) 286
Ulner nerve abscess in a multibacillary patient during post multidrug therapy surveillance. Abraham, S., *et al.* ..... (A) 255

Neutrophil(s),

Anti-neutrophil cytoplasmic antibodies (ANCA) in the clinical forms of leprosy. Breire, B. F. A., *et al.* ..... (O) 475
Effect of thalidomide on apoptosis of lymphocytes and neutrophils. Aseffa, A., *et al.* ..... (A) 87
Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin™) stimulates neutrophils and tissue macrophages and induced an effective nonspecific response against *M. avium* in mice. Bermudez, L. E., *et al.* ..... (A) 519

Nose,

Adherence of *M. leprae* to the nasal mucosa is influenced by surface integrity and viability. Sethna, B. K., *et al.* ..... (A) 269
Characterization of leprosy based on the nasal lipid profile. Srikanth, N. C., *et al.* ..... (A) 99
Computed tomographic study of paranasal sinuses in lepromatous leprosy. Sharma, V. K., *et al.* ..... (O) 201
[Detection of *M. leprae* and PGL-I antigen in nasal secretion and skin tissue.] Weng, X., *et al.* (A) 512
Intranasal anaesthesia in lepromatous leprosy. Soni, N. K ..... (A) 260
The nose in leprosy: immunohistology of the nasal mucosa. Fokkens, W. J., *et al.* ..... (O) 328

Obituaries,

Balina, Louis Maria. Valdez, R. P. ..... (Ob) 393
Hasselblad, Oliver W. Ross, W. F. ..... (Ob) 241
Jesudasan, Kumar. Sundar Rao, P. S. S. ..... (Ob) 68
Skinsnes, Olaf, F. Hastings, R. C. ..... (Ob) 243

Ofloxacin,

Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against *M. leprae* in mice and in lepromatous patients. Ji, B., *et al.* ..... (A) 399
Dr. Ganapati, *et al.* reply. Ganapati, R., *et al.* ..... (C) 391
High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Ji, B., *et al.* ..... (A) 81
[MDT plus ofloxacin in MB leprosy.] Zhu, R. ..... (A) 401
Multidrug-resistance to dapsone, rifampicin, and ofloxacin in *M. leprae*. Cambau, E., *et al.* .. (A) 249
Relapse of multibacillary leprosy after rifampin and ofloxacin treatment for 28 days; a case report. Ganapati, R., *et al.* ..... (C) 56
Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks. Ji, B. ..... (C) 391
[Shortening treatment duration of leprosy with MDT plus ofloxacin.] Xue, W., *et al.* ..... (A) 254

Pakistan,
Leprosy in Pakistan: LEPRA elective study. Ladhani, S ..... (A) 515

Pathology,
Pathology of eye in leprosy. Job, C. K., *et al.* ..... (A) 404
The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Sommer, C., *et al.* ..... (A) 303

Persisters,
Understanding the phenomenon of persistence in mycobacterial infections. Gupta, U. D. and Katoch, V. M. ..... (A) 277

Phagocyte(s),
Effects of mycobacteria on regulation of apoptosis in mononuclear phagocytes. Klinger, K., *et al.* ..... (A) 266
Identification of genetic loci implicated in the survival of *M. smegmatis* in human mononuclear phagocytes. Lagier, B., *et al.* ..... (A) 511

Pharmacokinetic(s),
Stability of rifampin in plasma: consequences of therapeutic monitoring and pharmacokinetic studies. LeGuellec, C., *et al.* ..... (A) 251

Phenolic glycolipid(s),
A simple dipstick assay for the detection of antibodies to phenolic glycolipid I of *M. leprae*. Buhrer, S. S., *et al.* ..... (A) 263
[A study of the sensitivity and specificity of the anti-PGL-I ELISA.] Brasil, M. T. L. R. F., *et al.* ..... (A) 504
Anti-PGL-I antibody levels in Thai leprosy patients. Kampirapap, K. and Singtham, N. .... (A) 266
Assessment of anti-PGL-I as a prognostic marker of leprosy reaction. Stefani, M. M. A., *et al.* (O) 356
[Detection of *M. leprae* and PGL-I antigen in nasal secretion and skin tissue.] Weng, X., *et al.* (A) 512
IgM anti-phenolic glycolipid I and IgG anti-10-kDa heat shock protein antibodies in sera and immune complexes isolated from leprosy patients with or without erythema nodosum leprosum and contacts. Rojas, R. E., *et al.* ..... (A) 92
Is PGL-I also present in *Leishmania donovani* promastigotes? Gupta, P. N. and Pal, N. K. .. (A) 505
[Serological surveillance wih PGL-I and LAM-beta for leprosy relapse.] Wang, D., *et al.* ... (A) 86

Phenotype(s),
Association of polymorphism at COL3A and CTLA4 loci on chromosome 2q31–33 with the clinical phenotype and *in vitro* CMI status in healthy and leprosy subjects: a preliminary study. Kaur, G., *et al.* ..... (A) 287
Bacille Calmette-Guerin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. Hoft, D. F., *et al.* ..... (A) 522
Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients. Queiroz, R. H. C., *et al.* ..... (A) 82

Polymerase chain reaction (PCR),
[A PCR for 26s rRNA of *M. leprae.*] Hou, W., *et al.* ..... (A) 97
Cloning of the antigen 85A from *M. gordonae* and its use for the specific PCR identification of these mycobacteria. Dumonceaux, M., *et al.* ..... (A) 110
Comparison of the ABI 7700 system (TaqMan) and competitive PCR for quantification of IS6110 DNA in sputum during treatment of tuberculosis. Desjardin, L. E., *et al.* ..... (A) 520
Detection of *M. tuberculosis* by PCR analysis of urine and other clinical samples from AIDS and non-HIV-infected patients. Sechi, L. A., *et al.* ..... (A) 119
Immunomagnetic separation and PCR for detection of *M. ulcerans*. Robert, B. and Hirst, R. .. (A) 118
Polymerase chain reaction assay for the detection and identification of *M. leprae* in patients in the United States. Scollard, D. M., *et al.* ..... (A) 411
Reverse transcription-PCR detection of *M. leprae* in clinical specimens. Kurabachew, M., *et al.* ..... (A) 415
Role of polymerase chain reaction in the diagnosis of early leprosy. Job, C. K., *et al.* ..... (A) 433
Stabilized, freeze-dried PCR mix for detection of mycobacteria. Klatser, P. R., *et al.* ..... (A) 415
[The multiplex polymerase chain reaction assay for the detection of *M. paratuberculosis* DNA in Crohn's disease tissue.] Al Shamali, M., *et al.* ..... (A) 107

Pregnancy,
Pregnancy in patients with Hansen's disease. Lyde, C. B. ..... (A) 257

Prostheses,
[The manufacture and improvement of simple artificial limbs for leprosy patients—analysis of 132 cases.] Xu, Y. ..... (A) 107

Protein(s),
Activation of CD8 T cells with specificity for mycobacterial heat shock protein 60 in *M. bovis* bacillus Calmette-Guerin vaccinated mice. Zugel, U. and Kaufmann, S. H. E. ..... (A) 94
An immunodominant epitope from mycobacterial 65-kDa heat shock protein protects against pristane-induced arthritis. Thompson, S. J., *et al.* ..... (A) 428
Antibodies to mycobacterial 65-kDa heat shock protein crossreact with the main mitochondrial antigens in patients with primary biliary cirrhosis. Vilagut, L., *et al.* ..... (A) 121
Beta$_2$-Glycoprotein I-dependent anticardiolipin antibodies as risk factor for reactions in borderline leprosy patients. Fiallo, P., *et al.* ..... (C) 387
Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Zea, A. H., *et al.* ..... (A) 272
Cloning, sequencing and expression of mig gene of *M. avium,* which codes for a secreted macrophage-induced protein. Plum, G., *et al.* ..... (A) 117
Crossreactivity of anti-10 kDa heat shock protein antibodies in leprosy and tuberculosis patients. Rojas, R. E., *et al.* ..... (A) 268
Determinant capture by MHC class II DR3 during processing of *M. leprae* 65 kDa heat shock protein by human B cells. Young, S. P., *et al.* ..... (A) 412
Dual multimodular class A penicillin-binding proteins in *M. leprae.* Lepage S., *et al.* ..... (A) 97
Effect of T-helper cytokine environment on specificity of T cell responses to mycobacterial 65,000 MW heat-killed shock protein. Siew, L. K., *et al.* ..... (A) 412
Expression and efficient export of enzymatically active *M. tuberculosis* glutamine synthetase in *M. smegmatis* and evidence that the information for export is contained within the protein. Harth, G. and Horwitz, M. A. ..... (A) 111
Expression of a gene for a porin-like protein OmpA family from *M. tuberculosis* H37Rv. Senaratne, R. H., *et al.* ..... (A) 525
Expression of monocyte chemotactic protein-3 in human monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. Vouret Craviari, V., *et al.* ..... (A) 272
Fractionation of mycobacterial integral membrane proteins by continuous elution SDS-PAGE reveals the immunodominance of low molecular weight subunits for human T cells. Mehrotra, J., *et al.* ..... (A) 97
Identification and characterization of a 29-kilodalton protein from *M. tuberculosis* culture filtrate recognized by mouse memory effector cells. Rosenkrands, I., *et al.* ..... (A) 511
Identification of iron-regulated proteins of *M. tuberculosis* and cloning of tandem genes encoding a low iron-induced protein and a metal transporting ATPase with similarities to two-component metal transport systems. Calder, K. M. and Horwitz, M. A. ..... (A) 421
Identification of potential CD8+ T-cell epitopes of the 19 kDa and AhpC proteins from *M. tuberculosis.* No evidence for CD8+ T-cell priming against the identified peptides after DNA-vaccination of mice. Erb, K. J., *et al.* ..... (A) 423
IgG subclass distribution of antibody responses to protein and polysaccharide mycobacterial antigens in leprosy and tuberculosis patients. Sousa, A. O., *et al.* ..... (A) 270
IgM anti-phenolic glycolipid I and IgG anti-10-kDa heat shock protein antibodies in sera and immune complexes isolated from leprosy patients with or without erythema nodosum leprosum and contacts. Rojas, R. E., *et al.* ..... (A) 92
Immunological characterization of five recombinant *M. leprae* proteins produced in *Escherichia coli.* Suzuki, Y., *et al.* ..... (A) 437
M. leprae binds to a 25-kDa phosphorylated glycoprotein of human peripheral nerve. Suneetha, L. M., *et al.* ..... (A) 412
Mammalian heterotrimeric G-protein-like proteins in mycobacteria: implications for cell signalling and survival in eukaryotic host cells. Shankar, S., *et al.* ..... (A) 282
Mycobacterial phagosome maturation, rab proteins, and intracellular trafficking. Deretic, V., *et al.* ..... (A) 264
[On method of large preparation and purification of recombinant alpha-protein antigen.] Yin, Y., *et al.* ..... (A) 513
Protein deficiency induces alterations in the distribution of T-cell subsets in experimental pulmonary tuberculosis. Mainali, E. S. and McMurray, D. N. ..... (A) 297

Protein synthesis is shut down in dormant *M. tuberculosis* and is reversed by oxygen or heat shock. Hu, Y. M., *et al.* ..... (A) 277
Schwann cell extracellular matrix protein production in modulated *M. leprae* and macrophage secretory products. Singh, N., *et al.* ..... (A) 100
Sequence data analysis reveals a relationship between LSR2, the recombinant fusion protein mimicking *M. leprae*, and VIF of bovine immunodeficiency virus (BIV). Ramakrishnan, S., *et al.* ..... (A) 281
Serum zinc, copper, magnesium, proteins and superoxide dismutase in leprosy patients on multidrug therapy—a follow up study. Sethi, N. C., *et al.* ..... (A) 259
Specific serological diagnosis of leprosy with a recombinant *M. leprae* protein purified from a rapidly growing mycobacterial host. Triccas, J. A., *et al.* ..... (A) 509
T-cell responses to major membrane protein II (MMP II) derived from *M. leprae* in leprosy patients. Ohyama, H., *et al.* ..... (A) 435

Psoriasis,
Psychiatric morbidity in leprosy and psoriasis—a comparative study. Bharath, S., *et al.* .... (A) 255
[Treatment of eruptive pustular psoriasis (von Zumbusch type) with thalidomide.] Poenca, N. G., *et al.* ..... (A) 301

Psychosocial,
[Knowledge and behavior on health care among leprosy patients.] Huang, S. ..... (A) 502
[Situations of persons cured of leprosy after returning home and community's response.] Xu, C., *et al.* ..... (A) 106

Purification,
[On method of large preparation and purification of recombinant alpha-protein antigen.] Yin, Y., *et al.* ..... (A) 513

Purified protein derivative (PPD),
Lymphocyte-dependent inhibition of growth of virulent *M. tuberculosis* H37Rv within human monocytes: requirement for CD4+ T cells in PPD-positive, but not PPD-negative subjects. Silver, R. F., *et al.* ..... (A) 303
The *in vitro* induction of human immunodeficiency virus (HIV) replication in PPD-positive HIV-infected persons by recall antigen response to *M. tuberculosis* is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. Goletti, D., *et al.* ..... (A) 424

Purine(s),
ATP-induced filling of mycobacteria by human macrophages is mediated by purinergic P2Z(P2X7) receptors. Lammas, D. A., *et al.* ..... (A) 113

Rat(s),
Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. Tingle, M. D., *et al.* ..... (A) 253
The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Sommer, C., *et al.* ..... (A) 303

Reaction, leprosy,
A sequential study of circulating immune complexes, complement and immunoglobulins in borderline tuberculoid leprosy patients with and without reactions. Ramanathan, V. D., *et al.* ..... (A) 507
Assessment of anti-PGL-I as a prognostic marker of leprosy reaction. Stefani, M. M. A., *et al.* (O) 356
Beta$_2$-Glycoprotein I-dependent anticardiolipin antibodies as risk factor for reactions in borderline leprosy patients. Fiallo, P., *et al.* ..... (C) 387
Contribution of type 1 reactions to sensory and motor function loss in borderline leprosy patients and the efficacy of treatment with prednisone. Roche, P. W., *et al.* ..... (O) 340
Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum. Rea, T. H. and Sieling, P. A. ..... (O) 316
Detection of S-100 antigen and anticeramide antibody in sera of leprosy patients with and without reaction. Narayan, R., *et al.* ..... (A) 268
[Histopathological feature of type 2 reaction in leprosy.] Wu, Y., *et al.* ..... (A) 406
IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type 2 lepra reaction on thalidomide treatment. Partida Sanchez, S., *et al.* ..... (A) 507

Leprosy reactions—complications of steroid therapy. Sugumaran, D. S. T. ..... (O) 10
Leprosy type 1 reaction as the first manifestation of borderline lepromatous leprosy in a young native German. Biedermann, T., *et al.* ..... (A) 401
Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like *M. leprae* T-cell reactivity in lesional skin—a follow-up study. Verhagen, C. E., *et al.* ..... (A) 272
Reversal reaction, nerve damage and steroid therapy in three multibacillary HIV positive patients. Arunthathi, S., *et al.* ..... (A) 500
Seizures following chloroquine treatment of type 2 lepra reaction: a case report. Ebenso, B. E. (A) 502
Serial Mitsuda tests for identification of reactional tuberculoid and reactional borderline leprosy forms. Lastoria, J. C., *et al.* ..... (O) 190
Study on the detection of leprosy reactions and the effect of prednisone on various nerves. Bernink, E. H. M. and Voskens, J. E. J. ..... (A) 84
The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987–1995. II. Reactions. Schreuder, P. A. M. ..... (O) 159
The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987–1995. I. Overview of the study. Schreuder, P. A. M. ..... (O) 149
The occurrence of reactions and impairments in leprosy: experience of the leprosy control program of three provinces in northeastern Thailand, 1987–1995. III. Neural and other impairments. Schreuder, P. A. M. ..... (O) 170

Rehabilitation,
[A survey of residential hygiene among leprosy patients.] Chen, J. ..... (A) 101
Delay in presentation and start of treatment in leprosy patients: a case-control study of disabled and non-disabled patients in three different settings in Ethiopia. Bekri, W., *et al.* ... (O) 1
[Efficacy of 18-month self-care in leprosy.] Wang, Q., *et al.* ..... (A) 518
[Efficacy of self-care for six years among 337 persons disabled by leprosy.] Shen, J., *et al.* .. (A) 420
[Feasibility of plastic surgery in rehabilitation for leprosy patients.] Liu, L., *et al.* ..... (A) 106
Joshi external stabilizing system (JESS) in proximal interphalangeal joint (PIP) contractures in leprosy. Salafia, A. and Chauhan, G. ..... (A) 288
Restoration of abduction-opposition in paralyzed thumb in leprosy. Sane, S. B., *et al.* ..... (A) 288
The metacarpophalangeal stabilization test: its surgical interest. Bourrel, P. ..... (A) 286

Relapse(s),
Association of HLA-class I antigens and haplotypes with relapse or pulmonary tuberculosis in patients treated with short course chemotherapy. Selvaraj, P., *et al.* ..... (A) 301
[Bacterial change and relapse after MDT in 157 cases of MB leprosy.] Li, W., *et al.* ..... (A) 400
High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Ji, B., *et al.* ..... (A) 81
[Relapse of 46 cases of leprosy in Wuxi, Jiangsu.] Li, B., *et al.* ..... (A) 498
Relapse of multibacillary leprosy after rifampin and ofloxacin treatment for 28 days; a case report. Ganapati, R., *et al.* ..... (C) 56
Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks. Ji, B. ..... (C) 391
[Relapses in leprosy; personal experience.] Terencio de las Aguas, J. ..... (A) 499
[Risk of relapse following FD MDT in leprosy.] Li, H., *et al.* ..... (A) 498
[Serological surveillance wih PGL-I and LAM-beta for leprosy relapse.] Wang, D., *et al.* ... (A) 86
Why relapse occurs in PB leprosy patients after adequate MDT despite they are Mitsuda reactive: lessons from Convit's experiment on bacteria-clearing capacity of lepromin-induced granuloma. Chaudhuri, S., *et al.* ..... (O) 182

Rifabutin,
The activity of rifabutin against *M. leprae* in armadillos. Dhople, A. M. and Williams, S. L. .. (A) 284

Rifampin,
Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against *M. leprae* in mice and in lepromatous patients. Ji, B., *et al.* ..... (A) 399
Characterization of rpoB mutations in rifampin-resistant clinical *M. tuberculosis* isolates from Greece. Matsiota Bernard, P., *et al.* ..... (A) 298
Crescentic glomerulonephritis due to rifampin treatment in a patient with pulmonary atypical mycobacteriosis. Ogata, H., *et al.* ..... (A) 252

Dr. Ganapati, *et al.* reply. Ganapati, R., *et al.* ..... (C) 391
Evaluation of a commercial probe assay for detection of rifampin resistance in *M. tuberculosis* directly from respiratory and nonrespiratory clinical samples. Gamboa, F., *et al.* ..... (A) 521
Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of *M. tuberculosis* complex and its resistance to rifampin. Rossau, R., *et al.* (A) 118
Factors affecting development of rifampicin resistance in biofilm-producing *Staphylococcus epidermidis*. Svensson, E., *et al.* ..... (A) 120
Flow cytometric testing of susceptibilities of *M. tuberculosis* isolates to ethambutol, isoniazid, and rifampin in 24 hours. Kirk, S. M., *et al.* ..... (A) 425
High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Ji, B., *et al.* ..... (A) 81
Multidrug-resistance to dapsone, rifampicin, and ofloxacin in *M. leprae*. Cambau, E., *et al.* .. (A) 249
Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against *M. avium*. Horgen, L., *et al.* ..... (A) 251
Relapse of multibacillary leprosy after rifampin and ofloxacin treatment for 28 days; a case report. Ganapati, R., *et al.* ..... (C) 56
Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks. Ji, B ..... (C) 391
Ribosylative inactivation of rifampin by *M. smegmatis* is a principal contributor to its low susceptibility to this antibiotic. Quan, S., *et al.* ..... (A) 98
Rifampicin causes false-positive immunoassay results for urine opiates. dePaula, M., *et al.* .. (A) 501
Rifampicin-induced urticaria in leprosy. Sharma, V. K., *et al.* ..... (A) 259
Rifampin and rifabutin and their metabolism by human liver esterases. Jamis Dow, C. A., *et al.* ..... (A) 80
Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes. Tentori, L., *et al.* ..... (A) 271
Stability of rifampin in plasma: consequences of therapeutic monitoring and pharmacokinetic studies. LeGuellec, C., *et al.* ..... (A) 251
The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Calleja, C., *et al.* ..... (A) 249
Update on rifampin drug interactions. Strayhorn, V. A., *et al.* ..... (A) 253
Use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide for rapid detection of rifampin-resistant *M. tuberculosis*. Mshana, R. N., *et al.* ..... (A) 426

Saliva,
[An investigation of ABH antigens in erythrocytes and saliva of leprosy patients.] Silva, E. A., *et al.* ..... (A) 502

Screening,
Green fluorescent protein reporter microplate assay for high throughput screening of compounds against *M. tuberculosis*. Collins, L. A., *et al.* ..... (A) 291

Sensation(s),
Correlation of oral surface temperatures and the lesions of leprosy. Scheepers, A. ..... (O) 214
Quantitative assessment of facial sensation in leprosy. Premkumar, R., *et al.* ..... (O) 348

Serum,
[Antibody to HIV-1 in the sera of leprosy patients.] Chan, J., *et al.* ..... (A) 85
Detection of S-100 antigen and anticeramide antibody in sera of leprosy patients with and without reaction. Narayan, R., *et al.* ..... (A) 268
Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Eriksson, T., *et al.* ..... (A) 293
[Examination of the sera of 278 leprosy (patients) with MLPA.] Zhao, G., *et al.* ..... (A) 273
Fractionation, characterization and diagnostic potential of circulating leprosy antigens isolated from sera of lepromatous leprosy patients. Narayan, R., *et al.* ..... (O) 22
IgM anti-phenolic glycolipid I and IgG anti-10-kDa heat shock protein antibodies in sera and immune complexes isolated from leprosy patients with or without erythema nodosum leprosum and contacts. Rojas, R. E., *et al.* ..... (A) 92
[TNF-alpha and SIL-2R in the sera of MB leprosy patients.] Gao, J., *et al.* ..... (A) 409

Skin,
Dapsone hydroxylamine inhibits the LTB4-induced chemotaxis of polymorphonuclear leukocytes into human skin: results of a pilot study. Wozel, G., *et al.* ..... (A) 83

[Detection of *M. leprae* and PGL-I antigen in nasal secretion and skin tissue.] Weng, X., *et al.* (A) 512
Epidemiological significance of first skin lesion in leprosy. Abraham, S., *et al.* (O) 131
Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like *M. leprae* T-cell reactivity in lesional skin—a follow-up study. Verhagen, C. E., *et al.* (A) 272
Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts. Nicolai, S., *et al.* (A) 115
[Treatment of ulcers on the heel with plantar aponeurosis—skin flap in leprosy.] Huang, S., *et al.* (A) 517
Type 1- and type 2-like skin-derived *M. leprae*-responsive T cell clones are characterized by coexpression of IFN-gamma/TNF-alpha and IL-4/IL-5/IL-13, respectively. Verhagen, C.E., *et al.* (A) 271

Skin smear(s),
Sensitivity and specificity of methods of classification of leprosy without use of skin-smear examination. Croft, R. P., *et al.* (O) 445
Skin smears in leprosy: is reduction in number of sites justified? Sujai, S., *et al.* (A) 260

Skin test(s),
An epidemic of tuberculosis with a high rate of tuberculin anergy among a population previously unexposed to tuberculosis, the Yanomami Indians of the Brazilian Amazon. Sousa, A. O., *et al.* (A) 303
Serial Mitsuda tests for identification of reactional tuberculoid and reactional borderline leprosy forms. Lastoria, J. C., *et al.* (O) 190
Why relapse occurs in PB leprosy patients after adequate MDT despite they are Mitsuda reactive: lessons from Convit's experiment on bacteria-clearing capacity of lepromin-induced granuloma. Chaudhuri, S., *et al.* (O) 182

Spain,
1998 Fontilles' cursos (N) 246

Spleen,
Susceptibility to *M. leprae* of ALY (alymphoplasia) mice and IFN-gamma induction in the culture supernatant of spleen cells. Yogi, Y., *et al.* (O) 464

Staining,
Choosing the decolourizer and its strength to stain *M. leprae*: does it really matter? de Soldenhoff, R., *et al.* (A) 510
Staining pattern of seven monoclonal anti-CD26 antibodies in leprosy: implications for the use of CD26 as a surrogate marker of a human Th1-like reaction. Seitzer, U., *et al.* (A) 412

Steroid(s),
Field treatment of acute nerve function impairment in leprosy using a standardized corticosteroid regimen—first year's experience with 100 patients. Croft, R. P., *et al.* (A) 256
Leprosy reactions—complications of steroid therapy. Sugumaran, D. S. T. (O) 10
Peptic ulcer and corticosteroid therapy. Arunthathi, S., *et al.* (C) 225
Reversal reaction, nerve damage and steroid therapy in three multibacillary HIV positive patients. Arunthathi, S., *et al.* (A) 500

Subclinical,
[Differences of subclinical infection rates and onset of leprosy between various villages in a high-endemic area.] Shen, J., *et al.* (A) 103

Sulfone(s),
Molecular modeling study on dapsone and sulfonamides comparing structures and properties with respect to antileprosy activity. Scior, T., *et al.* (A) 82

Superoxide,
Engineering a change in metal-ion specificity of the iron dependent superoxide dismutase from *M. tuberculosis* X-ray structure analysis of site-directed mutants. Bunting, K., *et al.* (A) 273
Serum zinc, copper, magnesium, proteins and superoxide dismutase in leprosy patients on multidrug therapy—a follow up study. Sethi, N. C., *et al.* (A) 259

Suppression,
Potential role of B7-1 and CD28 molecules in immunosuppression in leprosy. Agrewala, J. N., *et al.* ..... (A) 260

Surgery,
Essential Surgery in Leprosy; Techniques for District Hospitals by H. Srinivasan and D. D. Palande. Mathews, R. ..... (B) 69
[Feasibility of plastic surgery in rehabilitation for leprosy patients.] Liu, L., *et al.* ..... (A) 106
Joshi external stabilizing system (JESS) in proximal interphalangeal joint (PIP) contractures in leprosy. Salafia, A. and Chauhan, G. ..... (A) 288
Leprosy and renal transplantation. Date, A., *et al.* ..... (A) 403
Lid surgery to reduce discomfort produces an unexpected improvement in visual acuity—a case presentation. Thompson, K. ..... (A) 405
Restoration of abduction-opposition in paralyzed thumb in leprosy. Sane, S. B., *et al.* ..... (A) 288
The metacarpophalangeal stabilization test: its surgical interest. Bourrel, P. ..... (A) 286

Tanzania,
Evaluation of a sustained 7-year health education campaign on leprosy in Rufiji District, Tanzania. van den Broek, J., *et al.* ..... (A) 419
Survival of HIV-positive and HIV-negative leprosy patients in Mwanza, Tanzania. van den Broek, J., *et al.* ..... (C) 53

Testes,
Lepromatous orchitis associated with seminoma. Ebenezer, G. J., *et al.* ..... (E) 385
Osteoporosis due to testicular atrophy in male leprosy patients. Ishikawa, S., *et al.* ..... (A) 85

Testing,
Flow cytometric testing of susceptibilities of *M. tuberculosis* isolates to ethambutol, isoniazid, and rifampin in 24 hours. Kirk, S. M., *et al.* ..... (A) 425
Protective sensibility—its monofilament nylon threshold equivalents in leprosy patients. Malaviya, G. N., *et al.* ..... (A) 86
Two objective "archivable" tests for voluntary muscle testing in ulnar and median nerve paralysis. Bourrel, P. ..... (A) 286

Thailand,
Anti-PGL-I antibody levels in Thai leprosy patients. Kampirapap, K. and Singtham, N. .... (A) 266
The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987–1995. II. Reactions. Schreuder, P. A. M. ..... (O) 159
The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987–1995. I. Overview of the study. Schreuder, P. A. M. ..... (O) 149
The occurrence of reactions and impairments in leprosy: experience of the leprosy control program of three provinces in northeastern Thailand, 1987–1995. III. Neural and other impairments. Schreuder, P. A. M. ..... (O) 170

Thalidomide,
A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. Tsenova, L., *et al.* ..... (A) 526
A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. Marriott, J. B., *et al.* ..... (A) 298
Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Moreira, A. L., *et al.* ..... (C) 61
Effect of thalidomide on apoptosis of lymphocytes and neutrophils. Aseffa, A., *et al.* ..... (A) 87
Effect of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium. Dunzendorfer, S., *et al.* ..... (A) 292
Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Eriksson, T., *et al.* ..... (A) 293
Extravasation of leukocytes assessed by intravital microscopy: effect of thalidomide. Schneider, J., *et al.* ..... (A) 118

IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type 2 lepra reaction on thalidomide treatment. Partida Sanchez, S., *et al.* ..... (A) 507
In vitro and *in vivo* immunosuppressive potential of thalidomide and its derivative, N-hydroxy-thalidomide, alone and in combination with cyclosporin A. Pham Huy, C., *et al.* ..... (A) 300
Inhibition of IL-12 production by thalidomide. Moller, D. R., *et al.* ..... (A) 299
Novel biological response modifiers derived from thalidomide. Hashimoto, Y. ..... (A) 522
Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts. Nicolai, S., *et al.* ..... (A) 115
Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. Haslett, P. A. J., *et al.* ..... (A) 505
Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Stevens, R. J., *et al.* ..... (A) 304
Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome—a randomized, double-blind, placebo-controlled trial. Hamuryudan, V., *et al.* ..... (A) 295
Thalidomide may impede cell migration in primates by downregulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. McCarty, M. F. ..... (A) 114
Thalidomide protects mice against LPS-induced shock. Moreira, A. L., *et al.* ..... (A) 115
Thalidomide reduced MPTP-induced decrease in striatal dopamine levels in mice. Boireau, A., *et al.* ..... (A) 108
Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Or, R., *et al.* ..... (A) 299
The effect of thalidomide and two analogs on collagen induced arthritis. Oliver, S. J., *et al.* .. (A) 427
The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Sommer, C., *et al.* ..... (A) 303
The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. Haslett, P., *et al.* ..... (A) 111
The return of thalidomide: are birth defects surveillance systems ready? Yang, W. H., *et al.* .. (A) 305
The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Rovelli, A., *et al.* ..... (A) 301
[Treatment of eruptive pustular psoriasis (von Zumbusch type) with thalidomide.] Poenca, N. G., *et al.* ..... (A) 301
Was tumor necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? Argiles, J. M., *et al.* ..... (A) 518

Therapy (see also **Chemotherapy** and **Multidrug therapy**),
Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to *M. avium*. May, T., *et al.* .... (A) 114
[Effects of retreatment with MDT in persons cured of leprosy by using DDS monotherapy.] Mao, Q., *et al.* ..... (A) 498
[Effects of retreatment with MDT on 472 persons cured of leprosy with DDS monotherapy.] Wang, J., *et al.* ..... (A) 254
Leprosy reactions—complications of steroid therapy. Sugumaran, D. S. T. ..... (O) 10
Peptic ulcer and corticosteroid therapy. Arunthathi, S., *et al.* ..... (C) 225
Rational basis of interleukin-12 immunotherapy for established mycobacterial infection in mice. Kobayashi, K., *et al.* ..... (A) 434
Reversal reaction, nerve damage and steroid therapy in three multibacillary HIV positive patients. Arunthathi, S., *et al.* ..... (A) 500

Tissue(s),
[Detection of *M. leprae* and PGL-I antigen in nasal secretion and skin tissue.] Weng, X., *et al.* (A) 512
Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Or, R., *et al.* ..... (A) 299
[The multiplex polymerase chain reaction assay for the detection of *M. paratuberculosis* DNA in Crohn's disease tissue.] Al Shamali, M., *et al.* ..... (A) 107

Training,
1998 SLR&TC Karigiri course schedule ..... (N) 72
ALERT 1999 Training Calendar ..... (N) 395
Training for the handicapped in photography by VRC ..... (N) 76

Transmission,
A role for granulomatous inflammation in the transmission of infectious disease: schistosomiasis and tuberculosis. Doenhoff, M. J. ..... (A) 422
Anti-Contagionism in leprosy, 1884–1897. Pandya, S. S. ..... (E) 374
Does MDT arrest transmission of leprosy to household contacts? Vijayakumaran, P., *et al.* .. (O) 125
Leprosy transmission and mucosal immunity: towards eradication? Cree, I. A. and Smith, W. C. ..... (A) 514
MDT and transmission. Hastings, R. C. ..... (E) 224
Transmission and protection in leprosy: indications of the role of mucosal immunity. Ramaprasad, P., *et al.* ..... (A) 285

Transplantation,
Leprosy and renal transplantation. Date, A., *et al.* ..... (A) 403
The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Rovelli, A., *et al.* ..... (A) 301

Trial(s),
A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. Marriott, J. B., *et al.* ..... (A) 298
Exposure to pulsed magnetic fields in the treatment of plantar ulcers in leprosy patients—a pilot, randomized, double blind, controlled clinical trial. Sarma, G. R., *et al.* ..... (A) 288
Thalidomide in the treatment of the mucocutaneous lesions of the Behçcet syndrome—a randomized, double-blind, placebo-controlled trial. Hamuryudan, V., *et al.* ..... (A) 295
Use of different molecular typing techniques for bacteriological follow up in a clinical trial with AIDS patients with *M. avium* bacteremia. Picardeau, M., *et al.* ..... (A) 116

Tuberculin [see also **Purified protein derivative (PPD)**],
An epidemic of tuberculosis with a high rate of tuberculin anergy among a population previously unexposed to tuberculosis, the Yanomami Indians of the Brazilian Amazon. Sousa, A. O., *et al.* ..... (A) 303

Tuberculosis,
A controlled study of the influence of segregation of tuberculous patients for 1 year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Kamat, S. R., *et al.* ..... (A) 522
A role for granulomatous inflammation in the transmission of infectious disease: schistosomiasis and tuberculosis. Doenhoff, M. J. ..... (A) 422
Activity of amoxicillin/clavulanate in patients with tuberculosis. Chambers, H. F., *et al.* .... (A) 422
An epidemic of tuberculosis with a high rate of tuberculin anergy among a population previously unexposed to tuberculosis, the Yanomami Indians of the Brazilian Amazon. Sousa, A.O., *et al.* ..... (A) 303
Association of HLA-class I antigens and haplotypes with relapse or pulmonary tuberculosis in patients treated with short course chemotherapy. Selvaraj, P., *et al.* ..... (A) 301
Association of an HLA-DQ allele with clinical tuberculosis. Goldfeld, A. E., *et al.* ..... (A) 294
Circulating profile of Th1 and Th2 cytokines in tuberculosis patients with different degrees of pulmonary involvement. Dlugovitzky, D., *et al.* ..... (A) 89
Clinical correlates of interferon gamma production in patients with tuberculosis. Sodhi, A., *et al.* ..... (A) 119
Comparison of the ABI 7700 system (TaqMan) and competitive PCR for quantification of IS6110 DNA in sputum during treatment of tuberculosis. Desjardin, L. E., *et al.* ..... (A) 520
Crossreactivity of anti-10 kDa heat shock protein antibodies in leprosy and tuberculosis patients. Rojas, R. E., *et al.* ..... (A) 268
Cytokine patterns in tuberculosis and sarcoid granulomas— correlations with histopathologic features of the granulomatous response. Bergeron, A., *et al.* ..... (A) 87
DNA vaccines against tuberculosis. Lowrie, D. B., *et al.* ..... (A) 267
Development of new vaccines for tuberculosis; recommendations of the ACET. USA Advisory Council for the Elimination of Tuberculosis ..... (A) 526
Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant *M. tuberculosis*. Gadre, D. V., *et al.* ..... (A) 497
Effects of aminoguanidine on latent murine tuberculosis. Flynn, J. L., *et al.* ..... (A) 423

Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Baldwin, S. L., *et al.* ..... (A) 504
Genetic vaccination against tuberculosis. Lowrie, D. B., *et al.* ..... (A) 297
Genetics of host resistance and susceptibility to intramacrophage pathogens: a study of multicase families of tuberculosis, leprosy and leishmaniasis in northeastern Brazil. Blackwell, J. M. ..... (A) 262
IgG subclass distribution of antibody responses to protein and polysaccharide mycobacterial antigens in leprosy and tuberculosis patients. Sousa, A. O., *et al.* ..... (A) 270
Immunological requirements for a subunit vaccine against tuberculosis. El Hay, M. J. and Andersen, P. ..... (A) 423
Involvement of antilipoarabinomannan antibodies in classical complement activation in tuberculosis. Hetland, G., *et al.* ..... (A) 265
Leprosy and tuberculosis: the epidemiological consequences of cross-immunity. Lietman, T., *et al.* ..... (A) 285
Lethal tuberculosis in interleukin-6-deficient mutant mice. Ladel, C. H., *et al.* ..... (A) 91
Major histocompatibility complex restriction in tuberculosis susceptibility. Pitchappan, R. M., *et al.* ..... (A) 300
Pathogenesis of tuberculosis in mice exposed to low and high doses of an evironmental mycobacterial saprophyte before infection. Hernandez Pando, R., *et al.* ..... (A) 90
Protein deficiency induces alterations in the distribution of T-cell subsets in experimental pulmonary tuberculosis. Mainali, E. S. and McMurray, D. N. ..... (A) 297
The T cell receptor subsets of lymphocytes in bronchoalveolar lavage in patients with active pulmonary tuberculosis. Uh, S. T., *et al.* ..... (A) 428
The natural history of tuberculosis: the implications of age dependent risks of disease and the role of reinfection. Vynnycky, E. and Fine, P. E. M. ..... (A) 122
Trends in drug-resistant tuberculosis in the United States, 1993–1996. Moore, M., *et al.* ..... (A) 114
Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis. Juffermans, N. P., *et al.* ..... (A) 425
Two-dimensional electrophoretic analysis of humoral responses to culture filtrate of *M. bovis* BCG in patients with leprosy and tuberculosis. Naito, M., *et al.* ..... (O) 208
U.S.-Japan Cooperative Medical Science Program, Thirty-Third U.S.-Japan Tuberculosis and Leprosy Research Conference, Osaka, Japan, 8–10 July 1998 ..... (A) 430

U.K.,
CAB International titles on BioMedNet ..... (N) 246
CD-ROMS tackle global diseases. McDougall, A. C. ..... (N) 396
Forum for health informaton providers held. McDougall, A. C. ..... (N) 396
Stanley Browne/Acchiappati Fund sends delegates to 15th ILC. Durston, T. ..... (N) 495
"Sustaining leprosy Related Activities—Guidelines for Responding to Change"—new ILEP publication ..... (N) 77
Tropical Health for the 21st Century/4th Residential Meeting of the Royal Society of Tropical Medicine to be held ..... (N) 246

Ulcer(s),
A large localized outbreak of *M. ulcerans* infection on a temperate southern Australian island. Veitch, M. G. K., *et al.* ..... (A) 304
[Buruli ulcers in rural areas of Benin: management of 635 cases.] Aguiar, J. and Stenou, C. .. (A) 290
[Comprehensive control of plantar ulcers in leprosy.] Xu, M. ..... (A) 406
[Comprehensive treatment of 108 complicated plantar ulcers in leprosy.] Mao, Q., *et al.* .... (A) 517
Corneal ulcer caused by *Nocardia asteroides* in a patient with leprosy. Tendolkar, U. M., *et al.* (A) 260
Detection of *M. ulcerans* in environmental samples during an outbreak of ulcerative disease. Ross, B. C., *et al.* ..... (A) 118
[Effect of protective footwear on plantar ulcers.] Ma, J. ..... (A) 106
[Effects of protective footwear on preventing plantar ulcer.] Zhu, Z., *et al.* ..... (A) 290
Exposure to pulsed magnetic fields in the treatment of plantar ulcers in leprosy patients—a pilot, randomized, double blind, controlled clinical trial. Sarma, G. R., *et al.* ..... (A) 288
Neoplastic transformation of chronic ulcers in leprosy patients—a retrospective study of 12 consecutive cases. Kumaravel, S. ..... (A) 517
Peptic ulcer and corticosteroid therapy. Arunthathi, S., *et al.* ..... (C) 225
Phenytoin in the treatment of Buruli ulcer. Adjei, O., *et al.* ..... (A) 518

[Tepezcohuite: an alternative treatment for neurotrophic ulcers in leprosy; a case report.] Quintana Ginestar, M. V., *et al.* . . . . . (A) 106
The antimicrobial susceptibility of *M. chelonae* isolated from corneal ulcer. Hu, F. R., *et al.* . . (A) 112
[Treatment of ulcers on the heel with plantar aponeurosis—skin flap in leprosy.] Huang, S., *et al.* . . . . . (A) 517

Urine,
Detection of *M. tuberculosis* by PCR analysis of urine and other clinical samples from AIDS and non-HIV-infected patients. Sechi, L. A., *et al.* . . . . . (A) 119
Rifampicin causes false-positive immunoassay results for urine opiates. dePaula, M., *et al.* . . (A) 501

U.S.A.,
1997 Damien-Dutton Award to Roy E. Pfaltzgraff . . . . . (N) 70
1998 Damien-Dutton Award to Jean Margaret Watson . . . . . (N) 490
Call for nominations for 1999 Soper Award . . . . . (N) 397
Damien and Dutton, Two Josephs on Molokai by Howard E. Crouch. Hastings, R. C. . . . . (B) 488
8th International Congress on Infectious Diseases . . . . . (N) 78
New cases of leprosy in 1997 . . . . . (N) 495
9th Annual Tropical Health Update meeting in New Orleans . . . . . (N) 78
Polymerase chain reaction assay for the detection and identification of *M. leprae* in patients in the United States. Scollard, D. M., *et al.* . . . . . (A) 411
Trends in drug-resistant tuberculosis in the United States, 1993–1996. Moore, M., *et al.* . . . . (A) 114
U.S. leprosy cases in 1996 . . . . . (N) 78
9th Annual Tropical Health Update meeting in New Orleans . . . . . (N) 78
8th International Congress on Infectious Diseases . . . . . (N) 77

Vaccine(s), vaccination,
A case-control study of the effectiveness of the BCG vaccine for preventing leprosy in Yangon, Myanmar. Bertolli, J., *et al.* . . . . . (A) 101
[A leprosy elimination campaign combined with a vaccine against poliomyelitis, Rio de Janeiro, Brazil.] Andrade, V., *et al.* . . . . . (A) 399
Bacille Calmette-Guerin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. Hoft, D. F., *et al.* . . . . . (A) 522
DNA vaccines against tuberculosis. Lowrie, D. B., *et al.* . . . . . (A) 267
Development of new vaccines for tuberculosis; recommendations of the ACET. USA Advisory Council for the Elimination of Tuberculosis . . . . . (A) 526
Effectiveness of bacillus Calmette-Guerin (BCG) vaccination in the prevention of leprosy; a case-finding control study in Nagpur, India. Zodpey, S. P., *et al.* . . . . . (O) 309
Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Baldwin, S. L., *et al.* . . . . . (A) 504
Expression systems for study of mycobacterial gene regulation and development of recombinant BCG vaccines. DasGupta, S. K., *et al.* . . . . . (A) 520
[Follow up of 25 years for prevention of leprosy with BCG vaccination.] Ma, D., *et al.* . . . . . (A) 287
Genetic vaccination against tuberculosis. Lowrie, D. B., *et al.* . . . . . (A) 297
Identification and characterization of protective T cells in hsp 65 DNA-vaccinated and *M. tuberculosis*-infected mice. Bonato, V. L. D., *et al.* . . . . . (A) 263
Identification of potential CD8+ T-cell epitopes of the 19 kDa and AhpC proteins from *M. tuberculosis*. No evidence for CD8+ T-cell priming against the identified peptides after DNA-vaccination of mice. Erb, K. J., *et al.* . . . . . (A) 423
Immunological requirements for a subunit vaccine against tuberculosis. El Hay, M. J. and Andersen, P. . . . . (A) 423
Leprosy vaccine: influence of dissolved oxygen levels on growth of a candidate strain (*Mycobacterium w*), and storage stability of the vaccine. Mukhopadhyay, A., *et al.* . . . . . (A) 506
Studies of vaccination of persons in close contact with leprosy patients in Argentina. Bottasso, O., *et al.* . . . . . (A) 504
Vaccination against leprosy—the view from 1996. Fine, P. E. M. and Smith, P. G. . . . . (A) 102
Vaccination with plasmid DNA encoding mycobacterial antigen 85 stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by *M. tuberculosis* H37Rv infection. Denis, O., *et al.* . . . . . (A) 422
Vaccination with recombinant vaccinia viruses protects mice against *M. tuberculosis* infection. Zhu, X., *et al.* . . . . . (A) 123

Vasculitis,
A case of lymphocytic vasculitis with infiltration of dermal nerves resembling indeterminate leprosy. Job, C. K., *et al.* ..... (E) 49

Zimbabwe,
The National Leprosy Control Programme of Zimbabwe: a data analysis, 1983–1992. Wittenhorst, B., *et al.* ..... (A) 419

Zinc,
Serum zinc, copper, magnesium, proteins and superoxide dismutase in leprosy patients on multidrug therapy—a follow up study. Sethi, N. C., *et al.* ..... (A) 259